Loma Linda University

TheScholarsRepository@LLU: Digital Archive of Research,
Scholarship & Creative Works
Loma Linda University Electronic Theses, Dissertations & Projects
12-1999

A Preclinical Model of Ionizing Radiation and TNF-alpha Gene
Therapy for Cancer
Jun Li

Follow this and additional works at: https://scholarsrepository.llu.edu/etd
Part of the Microbiology Commons, and the Molecular Genetics Commons

Recommended Citation
Li, Jun, "A Preclinical Model of Ionizing Radiation and TNF-alpha Gene Therapy for Cancer" (1999). Loma
Linda University Electronic Theses, Dissertations & Projects. 1431.
https://scholarsrepository.llu.edu/etd/1431

This Dissertation is brought to you for free and open access by TheScholarsRepository@LLU: Digital Archive of
Research, Scholarship & Creative Works. It has been accepted for inclusion in Loma Linda University Electronic
Theses, Dissertations & Projects by an authorized administrator of TheScholarsRepository@LLU: Digital Archive of
Research, Scholarship & Creative Works. For more information, please contact scholarsrepository@llu.edu.

WWENSITY LIBRARY
l^tA LINDA, CALIFORNIA

LOMA LINDA UNIVERSITY
Graduate School

A PRECLINICAL MODEL OF IONIZING
RADIATION AND TNF-ALPHA GENE
THERAPY FOR CANCER
by

Jun Li

A Dissertation submitted in Partial Fulfillment
of the Requirements for the Degree of Doctor of
Philosophy in Microbiology and Molecular Genetics

December 1999

Each person whose signature appears below certifies that this dissertation in their opinion
is adequate, in scope and quality, as a dissertation for the degree Doctor of Philosophy.

,

(jy ^

a

. Chairperson
Daila S. Gridley, Professor of Microbiology & Molecular Genetics and Radiation
Medicine

Istvan Fodor, Professor of Microbiology & Molecular Genetics

'o

Jame:

. Kettering, Professor of Microbiol(|gy & Molecular Genetics

—V.

L

i\t

William H. Langridge, Professor dt Biochemistry

Grego:

. Nelson, Professor of Radiation Medicine

n

ACKNOWLEDGEMENTS
I would like to express my appreciation to the individuals who helped me
complete this study. I am grateful to Dr. Daila S. Gridley for her guidance,
encouragement and friendship by which she supported me through the research and the
preparation of this dissertation. I would also like to thank the other members of my
guidance committee, Dr. James D. Kettering, Dr. Greg Nelson, Dr. Istvan Fodor and Dr.
William Langridge, for their advice and comments.
I am grateful to Dr. Istvan Fodor for providing the plasmid vector. I would like to
express my appreciation to Dr. Jeffrey Cao for reviewing the tumor section. I would like
to thank Melba Andres, Tatyana Timiryasova, Bing Chen, Xiao-Wen Mao, Radha DuttaRoy, Georgia Peterson, Eric Kajioka, Peyman Haghighat, Dong Won Kim, Glen Miller,
Eric Zendejas for technical support and suggestions.
I would like to thank Greg Abell and Michael Moyers for their expert support on
cobalt and proton radiation. I am grateful to Dr. Lora Green for her advice and support. I
would also like to thank the members of Department of Microbiology and Molecular
Genetics and the Loma Linda Radiobiology Program for their help in my pursuit of the
degree.
Finally, I would like to thank my wife Qinhong Ma for her encouragement and
support through the years.
This work was supported in part by National Medical Technology Testbed grant
(sub-agreement no. 015-Fy98-LLU-Gridley) and National Aeronautics and Space
Administration grant NCC9-79.

in

TABLE OF CONTENT
LIST OF FIGURES
LIST OF TABLES.
ABBREVIATIONS
ABSTRACT...........

Vll

vm
IX
XI

CHAPTER ONE
I. INTRODUCTION
A.
B.
C.
D.
E.
F.
G.
H.

1

Overview of the problem.............
Radiation therapy.........................
Proton radiation therapy...............
Tumor necrosis factor-a (TNF-a)
TNF-a receptors...........................
Gene therapy................................
Gene delivery systems.................
Significance of study....................

1
2
4

8
11
12
16
19

CHAPTER TWO
II. MATERIALS AND METHODS

21

A. DNA purification.............................................................................
B. Purification of plasmid DNA by equilibrium centrifugation
in CsCl-ethidium bromide gradients...............................................
C. Cell lines...........................................................................................
D. pGLl-TNF-a construction and purification....................................
E. In vitro transfection of 6 cells...........................................................
F. Assay for TNF-a protein in conditioned medium............................
G. Activity of TNF-a protein expressed by pGLl-TNF-a transfected
C6 cells...........................................................................................
H. Immunofluorescence staining and quantitation of TNF-a receptors
by laser scanning cytometry (LSC)................................................
I. Animals, tumor induction and tumor volume...................................
J. Radiation specifications and procedures.........................................
K. 60Co irradiation of transfected C6 cells............................................
L. Phase I in vivo study: Expression of TNF-a protein in C6 tumor
xenografts inj ected with pGL 1 -TNF-a.........................................
M. Phase II in vivo study: Effect of pGLl-TNF-a, with and without
transfection reagent, on C6 tumors in combination with 60Co
radiation..........................................................................................
N. Phase III in vivo study: Effect of different doses of pGLl-TNF-a

iv

21
22
24
24
25
26
27
28
29
30
32
32
33

O.
P.
Q.
R.
S.
T.
U.
V.

on C6 tumors in combination with 60Cobalt radiation.............
Phase IV in vivo study: Effect of pGLl-TNF-a on C6 tumors
in combination with proton radiation.......................................
Phase V in vivo study: Comparison of pGLl-TNF-a effect on
C6 tumors in combination with 60Co and proton radiation.....
Spontaneous blastogenesis assay...............................................
EPS induced splenocyte proliferation assay...............................
Relative spleen weight and spleen and blood leukocyte counts.
Flow cytometry analysis of spleen and blood lymphocyte
population................................................................................
Hematological analysis.............................................................
Statistical analysis.....................................................................

34
34
35
35
36
37
37
39
40

CHAPTER THREE
41

III. RESULTS
A. Construction of TNF-a expressing plasmid pGLl-TNF-a....................
B. In vitro study of pGLl-TNF-a's effect on tumor cells with and
without cobalt radiation........................................................................
1. TNF-a expression by transfected C6 cells........................................
2. Effect of transfected C6 cell supernatant on L929 cell viability.......
3. TNF-a receptor quantitation by LSC...............................................
4. Effect of pGLl-TNF-a on transfected C6 cells in combination
with Cobalt radiation......................................................................
C. In vivo studies: Effect of pGLl-TNF-a and radiation on C6 xenograft
1. Phase I m vz'vo study: Expression of TNF-a protein in C6
tumor xenograft.............................................................................
2. Phase II in vivo study: Effect of pGLl-TNF-a, with and
without transfection reagent, on C6 tumors in combination
with 60Co radiation.........................................................................
3. Phase III in vivo study: Effect of pGLl-TNF-a in different
doses on C6 tumors in combination with 60Co radiation...............
4. Phase IV in vivo study: Effect of pGLl-TNF-a on C6 tumors
in combination with proton radiation............................................
5. Phase V in vivo study: Comparison of 60Co and proton radiation
effects on C6 tumors in combination with pGLl-TNF-a.............
6. Safety of DNA injection and radiation.............................................

41
41
41
44
44
52
52
52
73
85
97
98
103

CHAPTER FOUR
IV. DISCUSSION

106

A. Brief overview.............................................................
B. In vitro analysis of pGL-TNF-a's effect on transfected
v

106

C6 cells............................................................................................

C. In vivo expression of TNF-a protein in C6 tumor xenograft
Injected with pGLl-TNF-a..............................................................
D. TNF-a receptor quantitation by LSC.................................................
E. Effect of pGLl-TNF-a on transfected C6 cells in combination
with 60Co radiation in vitro................................................................
F. Effect of polyamine transfection agent on the combination treatment
G. Effect of pGLl-TNF-a on C6 tumors in combination with 60Co radiation..
H. Effect of pGLl-TNF-a in different doses on C6 tumors
in combination with 60Co radiation.................................
I. Effect of treatment schedule on pGLl-TNF-a and proton
radiation combination treatment of C6 tumor.................
J. Comparison of pGLl-TNF-a’s effect on C6 tumors in
combination with 60Co radiation and proton radiation....
K. Effect of treatments on lymphocyte populations and
WBC activity of C6 tumor bearing mice........................
L. Tumor histopathology.......................................................
M. Future studies....................................................................

108
108
111
112
113
114

114
116
117
121
124
126

CHAPTER FIVE
V.

CONCLUSIONS

128

VI.

APPENDIX 1

132

VII. APPENDIX 2

140

VIII. LITERATURE CITED

148

vi

LIST OF FIGURES
Figures

page

1. Characteristics of ionizing radiation.....................................................
2. Model for the enhancement of TNFR60-induced cell death by
costimulation of TNFR80...............................................................
3. Scheme of plasmid pGLl-TNF-a construction.....................................
4. TNF-a expression in pGLl-TNF-a transfected C6 glioma cells..........
5. Photographs of TNF receptors expressed on C6 glioma cells...............
6. Histograms of fluorescence intensity indicating presence of
receptors on C6 and L929 cells.......................................................
7. Effect of combination of pGLl-TNF-a and cobalt radiation on C6
glioma cell growth in culture.........................................................
8. Phase I in vivo: TNF-a expression by intratumorally injected
pGLl-TNF-a in C6 tumor-bearing athymic mice..........................
9. Data sheet sample generated by flow cytometry...................................
10. B and NK cell determination by flow cytometry.................................
11. Effect of pGLl-TNF-a on blood B cell percentage in C6 tumor
bearing athymic mice.....................................................................
12. Effect of pGLl-TNF-a on blood NK cell percentage in C6 tumor
bearing athymic mice......................................................................
13. Phase I in vivo study: Spontaneous blastogenesis of peripheral blood
14. Phase II in vivo study: C6 tumor progression in athymic mice
treated with pGLl-TNF-a and cobalt radiation with/without
SuperFect TM
15. Phase II in vivo study: C6 tumor progression in athymic mice treated
with pGLl-TNF-a and cobalt radiation............................................
16. Phase II in vivo study: spontaneous blastogenesis of peripheral blood.
17. Phase II in vivo study: stimulation index of splenocytes upon EPS
stimulation........................................................................................
18. Phase III in vivo study: C6 tumor progression in athymic mice treated
with different doses of pGLl-TNF-a and cobalt radiation...............
19. H & E staining of C6 tumor xenograft in athymic mice........................
20. Hemorrhage and early stage necrosis in C6 tumor................................
21. Different stages of necrosis and neutrophil infiltration in C6 tumor.....
22. Phase IV in vivo study: C6 tumor progression in athymic mice treated
with pGLl-TNF-a and proton radiation...........................................
23. Phase V in vivo study: C6 tumor progression in athymic mice treated
with pGLl-TNF-a and cobalt or proton radiation............................

vn

7
14
43
46
49
51
54
57
61
63
68
70
72
76
79
82
87
86
92
94
96
100
102

LIST OF TABLES
page

Tables
1. Effect of conditioned medium from pGLl-TNF-a/polyamine
transfected C6 cells on L929 cell viability......................................
2. Analysis of hematological parameters................................................
3. WBC, percentage of lymphocytes and percentage of monocytes/
granulocytes in blood.......................................................................
4. Percentages of T cells and their subsets in the blood lymphocyte
population........................................................................................
5. Numbers of T cells and their subsets in the blood...............................
6. B and NK cell counts in the blood.......................................................
7. Phase II in vivo study: White blood cell counts and relative spleen
weights..............................................................................................
8. Phase III in vivo study: White blood cell counts and relative spleen
weights..............................................................................................
9. Phase III in vivo study: Whole blood spontaneous blastogenesis and
spleen cell stimulation index............................................................
10. Phase V in vivo study: White blood cell counts and relative spleen
weights..............................................................................................
11. Phase V in vivo study: Whole blood spontaneous blastogenesis and
spleen cell stimulation index............................................................

vm

47
58
64
65
66
74
80
88
89
104
105

ABBREVIATIONS

APC

Allophycocyanin

CAT

Chloramphenicol acetyl transferase

CD

Cluster of differentiation

CM

Conditioned medium

CMV

Cytomegalovirus

CNS

Cental nervous system

Co

Cobalt

DMEM

Dulbecco's minimum essential medium

dpm

Disintegrations per minute

ELISA

Enzyme-linked immunosorbent assay

FADD

Fas-associated protein with death domain

FACS

Fluorescence activated cell sorter

FITC

Fluorescein isothiocyanate

Gy

Gray

H&E

Hematoxylin and Eosin

Hct

Hematocrit

Hgb

Hemoglobulin

IL-1

Interleukin-1

IM

Intramuscular(ly)

IP

Intraperitoneal(y)

IV

Intravenous(ly)

LB

Luria-Bertani medium

LET

Linear energy transfer

LSC

Laser scanning cytometry

LPS

Lipopoly saccharide

MAb

Monoclonal antibody

MHC

Major histocompatibility complex

MORT1

Mediator of receptor-induced toxicity-1

ix

NIST

National Institute of Standards and Technology

PBS

Phosphate buffered saline

PE

Phycoerythrin

PerCP

Peridinin chlorophyll protein

Pit

Platelets

PKC

Protein kinase C

PMN

Polymorphonuclear

RBC

Red blood cells

RBE

Relative biological effectiveness

RPMI

Roswell Park Memorial Institute

SC

Subcutaneous(ly)

SSC

Side scatter

TdR

thymidine deoxyribonucleotide

TE

Tris EDTA

Tc

T cytotoxic lymphocytes

Th

T helper lymphocytes

TNF-a

Tumor necrosis factor-a

TNFR

TNF receptor

TRAF1

TNF receptor associated factor 1

TRAF2

TNF receptor associated factor 2

WBC

White blood cells

x

ABSTRACT OF THE DISSERTATION
A Preclinical Model of Ionizing Radiation and
TNF-Alpha Gene Therapy for Cancer

by

Jun Li
Doctor of Philosophy, Graduate Program in Microbiology and Molecular Genetics
Loma Linda University, December, 1999
Dr. Daila S. Gridley, Chairperson

Long term control of high-grade brain tumors is rarely achieved with current
therapeutic regimens. This study sought to determine if pretreatment with plasmid DNA
expressing Tumor Necrosis Factor-a (TNF-a) could enhance the effect of ionizing
radiation in an aggressive, rapidly growing glioma tumor (C6) model. Plasmid DNA is
an attractive vector system for delivery of foreign genes into eukaryotic cells due to its
advantages including low immunogenicity in vivo, lesser toxicity and relatively low cost.
We have constructed a plasmid-based mammalian expression vector (pGLl-TNF) to
secrete human TNF-a from cancer cells. Plasmid DNA was successfully transfected into
C6 cells in vitro by using a polyamine-facilitated method. Expression from transfected
cells was detected for up to 7 days and averaged 0.4 ng TNF-a in the conditioned
medium (CM) from 1 x 105 cells. Using Laser Scanning Cytometry, we confirmed that

xi

both P55 and P75 receptors for TNF-a were present on the C6 cell membrane. P55
receptors are expressed at significantly higher levels than P75 receptors. The expressed
TNF-a alone did not inhibit growth of the transfected C6 cells; neither did it modulate
radiation-induced inhibition of C6 cell proliferation in vitro. When plasmid pGLl-TNF
was injected intratumorally, the injected tumors expressed significant amount of TNF-a.
The TNF expressed was measurable up to 7 days after injection. In the in vivo tests,
pGLl-TNF-a injected intratumorally 18-24 hr before radiation (Cobalt or Proton)
significantly inhibited the C6 xenograft tumor progression compared to control groups.
This effect was more than additive, since pGLl-TNF alone did not slow tumor growth.
Blood and spleen cell population analyses showed significant change in percentages of
Nature Killer and B cells in blood and spleen. Tumor histopathology revealed an earlier
necrosis appearance in combination-treated tumors. The results suggest the radiation
sensitizing effect of TNF-a in vivo is indirect, through multiple routes rather than any
single major factor. Future studies should focus on improving the current treatment
regimen and to explore the combination of radiation and other genetically delivered
antitumor agents against more different forms of tumor.
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CHAPTER ONE
INTRODUCTION

A. Overview of the problem
According to American Cancer Society estimates, 1,284,900 new cancer cases
will be diagnosed and 563,100 cancer-related deaths will occur in the U.S.A. in 1999
(Landis et al., 1999). These estimates do not include basal and squamous cell skin
cancers, with 1 million new cases expected this year. In spite of immense efforts to
improve treatments and find cures, the overall mortality for many advanced forms of
cancer has not declined in the last two or three decades. Furthermore, the failure to
achieve local control of tumor remains a fatal problem in 100,000 patients each year in
the United States.
Although brain tumors are not among the most frequent tumors in the human
population, they are among the most deadly. Approximately 35,000 new cases of
primary adult neoplasms of the central nervous system (CNS) are diagnosed in the U.S.A.
annually. Several studies have also noted a constant increase in incidence rates for
primary brain tumors in the elderly population (Laws, 1993). In children, tumors of the
CNS constitute the largest group of solid neoplasms and are second only to leukemia in
their overall frequency during childhood. Each year, brain tumors develop in
approximately 1,500 - 2,000 children in the U.S.A. (Cohen et al., 1994). Despite
considerable improvements in radiation, chemotherapy, and neurosurgical techniques
during the last decades, curative therapy for high-grade brain tumors in both adults and
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children has been extremely rare (Prados et al., 1998). The outcome of conventional
therapeutic approaches toward treatment of glioblastomas is still one of the poorest in
medicine; the median survival time is only 1 year from the time of diagnosis (Loeffler et
al., 1992). In children with brain tumors, the overall survival is better than in adults,
mostly because of the sensitivity of medulloblastomas and oligodendrogliomas to
radiation and chemotherapy (Caimcross et al., 1992). However, pediatric brainstem
gliomas have remained resistant toward all conventional therapies with a median survival
of less than 1 year after diagnosis. CNS irradiation and intrathecal application of
chemotherapeutic drugs in children can also cause long-term side effects, ranging from
cognitive defects (Pollack, 1994) to second primary CNS neoplasms (Hawkins et al..
1987). Thus, there is an urgent need to explore new treatments for brain tumors, both in
adults and children.
B. Radiation Therapy
Since their discovery by Roentgen almost a century ago, ionizing radiation has
played a major role in modem medicine. X- and y-rays constitute part of the continuous
spectrum of electromagnetic (EM) radiation that includes radio waves, heat, and visible
and ultraviolet (UV) light. All types of EM radiation can be considered as moving
packets (quanta) of energy called photons. When X-ray photons interact with tissue, they
give up energy by three processes: the photoelectric effect, the Compton effect, or pair
production (Johns and Cunningham, 1983). In the energy range most widely used in
radiotherapy (100 keV to 20 MeV), the Compton effect is the most important mechanism
leading to deposition of energy in biological materials. This energy-transfer process
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involves a billiard-ball type of collision between the photon and an outer orbital electron
of an atom, with partial transfer of energy to the electron and scattering of the photon into
a new direction. The electron (and the photon) can then undergo further interactions,
causing more ionizations and excitations, until its energy is dissipated. All three of the
interaction processes mentioned above result in the production of energetic electrons that,
in turn, lose energy by exciting and ionizing target atoms and molecules and setting more
electrons in motion.
Today, approximately 50% percent of all cancer patients in the U.S.A., and many
other industrialized countries, will receive radiation at some time during their treatment
(Coia et al., 1994). This includes the great majority of individuals with malignant
gliomas. With a sufficient absorbed dose, radiation can control localized cancer.
Because of the inability to selectively irradiate the cancer, however, normal adjacent
tissues are also irradiated, resulting in various side effects. As a consequence, a less than
optimal total dose is frequently used to reduce the incidence of unacceptable normal
tissue damage. Furthermore, the total radiation dose needed for cure and the patient’s
capacity to tolerate the treatment are often variable and unpredictable. A total dose of 54
Gray (Gy), delivered daily in 30 fractions of approximately 1.8 - 2.0 Gy/fraction, to the
tumor plus a 2 cm margin around the identified mass is a commonly used procedure for
high grade primary tumors of the brain. This time-dose regimen, however, fails all too
often to completely eradicate the disease. In about 90% of children with high-grade brain
tumor, the tumor recurs within the irradiated field because the prescribed dose was
insufficient (Archambeau 1991; Leibel and Sheline, 1985). Attempts to maximize the
probability for cure by increasing the dose of radiation (i.e., stereotactic radio-surgery
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and focal radiation “boost” administered with brachytherapy) can result in unacceptable
damage to normal tissue with only a very modest increase in local control and survival
time (Alexander et al. 1993; Gutin et al. 1987; Shrieve et al. 1995; Wilson et al. 1992).
High doses of brain irradiation can result in radio-necrosis, edema, and serious
intellectual, motor and sensory impairment (Leibel et al. 1987). Long term use of
glucocorticoid and repeated surgical interventions are often required to decrease the risk
for serious complications (Salcman 1966). It is clear that new therapeutic approaches are
needed to augment existing therapies for improved management of these diseases. Many
investigators have turned to combining radiation-sensitizing agents (e.g.,
fluoropyrimidines, thymidine analogs, and hydroxyurea) with external beam radiation in
an effort to enhance the overall therapeutic effects (Bernhard et al.,1996; Cook et al.,
1992; Gregoire et al., 1994; Pu et al., 1995; Urtasun et al., 1993). At best, these studies
have achieved only modest success and many have been plagued by rapid breakdown of
the infused agent, as well as toxicity to rapidly dividing normal tissues in the bone
marrow and intestinal tract.
C. Proton Radiation Therapy
Another approach to improving the effect of tumor radiotherapy is to reduce the
dose delivered to surrounding normal tissues while increasing the tumor dose. Irradiation
of tumors with heavy particles, instead of y-radiation (photons), is an option that is being
used with increasing frequency. Protons have recently emerged as the heavy particle of
choice for radiotherapy. The dose distribution along the range of a proton beam can
allow the therapist to reduce the dose delivered to normal tissues by a factor of 2 to 5
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(Archambeau and Bennet, 1972; Archambeau et al., 1994). Charged particles, such as
protons and other heavy ions, lose energy by continuous interactions with electrons, and
through occasional nuclear events within the absorbing medium. Thus, unlike photons
which are absorbed by exponential attenuation, charged particles have a finite range and
deposit energy in an inverse relationship with their velocity. Heavy charged particles,
such as protons, follow relatively straight paths and, therefore, have well defined edges
and a sharp Bragg peak near the end of their range, where the velocity approaches zero.
Figure 1 illustrates the characteristics of dose distribution of both types of radiation.
Proton radiation produces a rapid fall-off of absorbed dose at the distal stopping edge,
and a low level of lateral scatter, which results in sharp lateral beam edges. Electrons, by
comparison, have a diffuse energy deposition pattern because of multiple, wide-angle
scattering. Heavier ions, such as carbon and neon, have even sharper beam edge
characteristics than protons but are subject to fragmentation events that create range
unsharpness. Thus, proton beams appeared to have an ideal dose distribution
characteristics for radiation treatment.
Loma Linda University Medical Center is recognized as a leader in radiation
treatment of cancer through its establishment of the world’s first, largest, and most
comprehensive hospital-based proton treatment facility (Slater et al. 1988; Slater et al.
1991). Proton beam therapy has the potential to realize higher cure rates with fewer side
effects than conventional radiation. Recent data from prostate cancer patients treated
with proton radiation at LLUMC show minimal treatment-related toxicity and excellent
normalization of prostate specific antigen (PSA) in serum and disease-free survival
(Yonemoto et al. 1997, Slater et al. 1998). These findings are very encouraging since the
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Figure 1. Character of ionizing radiations.
Depth dose curves (relative percent
dose versus depth in tissue) for an unmodulated proton beam (Bragg peak), a modulated
proton peak (spread out Bragg peak or SOBP), and 10 MV x-rays.
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total radiation dose delivered was 10-15% higher than what is usually administered with
conventional radiation techniques. Excellent response with acceptable risks have also
been obtained with skull base chordomas and chondrosarcomas in patients treated with
fractionated proton therapy (Hug et ah, 1999). In addition, promising results have been
reported with proton treatment of subfoveal choroidal neovascularization in age-related
macular degeneration, a major cause of legal blindness in the U.S.A. (Yonemoto et al.
1996; Moyers et al., 1999). The proton beam in this latter study was stopped in the
orbital cavity, delivering no primary proton dose to the brain. Currently, more than 4,000
patients have been treated at the Proton Treatment Center since its opening in 1990.
D. Tumor Necrosis Factor-a (TNF-a)
TNF-a is a multifunctional polypeptide with a molecular weight of 17-kDa. It is
produced primarily by activated cells of the monocyte-macrophage lineage. Among its
numerous biological effects are induction of hemorrhagic necrosis of tumors through
destruction of tumor vasculature, direct cytotoxicity against tumor cells, induction of
inflammation, and enhancement of tumoricidal activities of macrophages, neutrophils,
and cytotoxic T lymphocytes. (Carswell et al., 1975; Hemandez-Caselles and Stutman
1993; Old et al., 1988; Robinet et al., 1990; Shalaby et al., 1985; Talmadge et al., 1988;).
However, serious side effects, including hypotension, metabolic acidosis and respiratory
distress have been noted with systemic administration of high-dose TNF-a, thereby
limiting its use as a sole therapeutic agent (Creaven et al., 1987; Hallahan et al., 1993;
Hersh et al., 1991). The maximum tolerated dose of TNF-a in the human is
approximately 40-fold less compared to the mouse on a weight-by-weight basis (Sherman
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et al., 1988). Localized treatment with the agent, however, can reduce risk for toxicity
(Pfreundschuh et al., 1989) and induce dramatic antitumor effects when used with certain
chemotherapeutic drugs (Eggermont et al., 1996).
It has been demonstrated that TNF-ct can induced hydroxyl radical production in
sensitive cell types, resulting in DNA damage and apoptosis (Rubin et al., 1988;
Yamauchi et al., 1989; Zimmerman et al., 1989). The induction of apoptosis by TNF-a
is thought to be at least partly due to upregulation of wild-type p53 expression in
susceptible cells (Zimmerman et al., 1996). These antitumor mechanisms have recently
been also associated with the tumoricidal effects of radiation (Heilman et al., 1995; Jarvis
et al., 1996; Ling et al., 95). In addition, there is convincing evidence that both TNF-a
(after binding to its p55 receptor) and ionizing radiation (possibly through energy transfer
to membranes) can generate the lipid messenger ceramide through the sphingomyelin
signalling pathway, leading to the induction of apoptosis (Jarvis et al., 1996).
Previous studies conducted in our laboratories with human colon and lung tumor
xenografts, both of which are relatively radiosensitive tumor types, showed that
pretreatment with TNF-a protein can significantly enhance the antitumor effects of
radiation (Gridley et al., 1994a, 1994b; 1995). More recently, we have made similar
observations in the C6 rat glioma model (Gridley et al., 1997), a tumor type that is among
the most radioresistant. Relatively low doses of the cytokine were given intravenously
(IV) in our studies in order to avoid systemic toxicity. Others have shown that TNF-ainduced side effects can be avoided by intratumoral administration (Bartsch et al., 1989).
Sersa et al. (1988) found that TNF-a, when given systemically together with radiation,
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resulted in a more than additive increase in the radioresponse of two murine tumors, as
well as reduced radiation damage to bone marrow progenitor cells. A phase I clinical
trial by Hallahan et al. (1995) showed that in some patients, locally advanced tumors can
be controlled by lower than expected doses of radiation when combined with
systemically administered TNF-a protein. However, major toxicities that were
independent of the cytokine dose required withdrawal of a number of patients from the
study.

TNF-a also has potent immunomodulatory properties, including upregulation of
T and B lymphocyte proliferation, activation of macrophages, granulocytes, endothelial
cells and fibroblasts, and induction of cell surface markers (e.g., MHC class II antigens)
and cytokines (e.g., IL-1) (Old, 1985; Ghiara et al., 1987; Kehrl et al., 1987; Scheurich et
al., 1987; Philip et al., 1986). It is a major inflammatory cytokine that promotes leukocyte
recruitment and survival (Sarraf, 1994, Pilaro et al., 1994, Hemandez-Caselles et al.,
1995). Some of these characteristics of TNF-a serve to amplify innate immune
mechanisms which, in turn, set the stage for optimal activation of specific immunity.
Since athymic mice have few functional T lymphocytes, it is important to note that
nonspecific, innate immune mechanisms can exhibit strong antitumor effects. Decreased
tumorigenicity and invasiveness have been reported in athymic mice treated with murine
fibrosarcoma cells that have been genetically engineered to secrete TNF-a (Sarraf 1994).
In similar TNF-a gene therapy studies, Blankenstein et al. (1991) have shown that the
cytokine inhibits murine plasmacytoma growth in BALB/c mice indirectly through
chemotactic recruitment and activation of cells that are predominantly macrophages.
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These investigators also found that extremely low doses of TNF-a were sufficient to
induce tumor regression. Dramatic tumor responses have been recently reported in both
preclinical and clinical studies employing isolated limb perfusion and other techniques in
which the administration of TNF-a protein was localized and used together with
chemotherapeutic drugs (Manusama et ah, 1994; Eggermont et ah, 1996). In some of
these studies, it was found that TNF-a leads to a prominent inflammatory response
within tumors that is characterized by presence of macrophages and granulocytes
(Eggermont et ah, 1996). These and other investigations support the contention that
failure of the immune system to wage a significant attack against tumor cells may be due
(at least partly) to insufficient cell activation and that TNF-a-mediated activation of
nonspecific immunological mechanisms can contribute to the control of neoplastic
growth.
E. TNF-a receptors
The effects of TNF-a are mediated by binding to cell-surface receptors. Two
TNF-a receptors have been identified. The type I receptor (TNF-R55-60, P55-60) has a
molecular weight of 55-60 kDa while the type II receptor (TNF-R75-80, P75-80) has a
molecular weight of 75-80 kDa (Callard et al., 1994). Both are members of the nerve
growth factor family of receptors. These two receptors have less than 25% homology
with each other with no significant homology between the intracellular domains (Dembic
et al., 1990). In fact, none of the TNFR superfamily members possesses sequences
implying any known catalytic activity. It is not surprising that these two receptors are
linked to different signaling mechanisms. TNF-R75-80 has been shown to induce
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arachidonic acid production (Grell et al., 1994). The cytoplasmic domain of TNF-R7580 is associated with a novel family of molecules, TNF receptor associated factor 1
(TRAF1) and 2 (TRAF2), which may serve as signal transducers (Rothe et al., 1994).
TNF-R55-60 has been shown to stimulate the activation of pKC, sphingomylinase,
phospholipase A2 as well as inducing the production of DAGs and ceramide (Wiegmann
et al., 1992). Furthermore, TNF-R55-60 induces a yet unidentified serine kinase whose
activity is not altered by inhibitors of pKA and pKC (VanArsdale et al., 1994). In recent
studies, it was reported that over expression of TNFR80 greatly enhanced TNFR60mediated cytotoxicity and this process required the TRAF2 binding site on TNFR60
(Weiss et al., 1997). Furthermore, it was found that TNFR80-dependent enhancement of
TNFR60-mediated cell death occurs upstream of Fas-associated protein with death
domain and Mediator of receptor-induced toxicity-1 (FADD/MORT1) or on a separate
TNFR60-induced pathway, and that TRAF2 is involved in both positive and negative
regulation of TNF-induced apoptosis (Weiss et al., 1998). The proposed model of both
receptors’ role is shown in Figure 2. It was evident from these studies that the presence
and the distribution of these two types of receptors would probably greatly affect the
sensitivity of a certain cell type to TNF-a.
F. Gene therapy

Gene therapy is defined as the treatment of diseases by transferring therapeutic
genes into target cells. The first gene therapy clinical trial was performed successfully in
1990 with two children suffering from adenosine deaminase (ADA) gene deficiency
syndrome (Bordignon et al., 1995; Blaese et al., 1995). Since then gene therapy has
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Figure 2. Model for the enhancement of TNFR60-induced cell death by
costimulation of TNFR80. A, TNF simultaneously triggers the preexisting apoptotic
pathway and the NF-KB-dependent synthesis of antiapoptotic factors (NDPF). B, Cell
death is enhanced, when the cytoplasmic concentration of NDPFs is diminished by
TNFRSO-induced inactivation/degradation, (cited from T. Weiss, et al., 1998)
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become one of the most promising weapons in the battle against deadly diseases such as
cancer and AIDS (Anderson, 1998), as well as autoimmune and inflammatory diseases
(Seroogy e? a/., 1998).
Gene therapy may be a potentially revolutionary change to modem medicine.
Although tremendous progress has been achieved in the fields of anesthesia, vaccination,
transplantation, and radiotherapy, humans are still vulnerable to a wide variety of
inherited and acquired diseases. Newly emerging diseases, such as AIDS, make it
necessary to develop new forms of medical treatment. Compared to other forms of
therapeutic approaches involving protein or antibodies, gene therapy has several
advantages. For example, when compared to protein therapy, a gene therapy approach
would eliminate the possible endotoxin contamination present during protein preparation
and purification. It would also be more stable for storage and transport and decrease the
cost of preparation. Unlike radiotherapy and chemotherapy, gene therapy seeks to target
specific cells or induce a specific immune response for therapeutic purposes. There are
over 125 clinical trials that have been approved since 1990 in the United States alone, and
329 clinical studies with over 2,500 patients have been initiated world wide since 1989
(Gottschalk et al., 1998; Anderson, 1998). There are a wide variety of human genetic
diseases, acquired diseases, and infectious diseases that have been selected for potential
gene therapy treatment.
The majority of gene therapy strategies have fallen into one of the following three
categories: a) genetically modified tumor vaccines, in which metastatic cancer cells from
a patient are extracted, transfected ex vivo with one of several functional cytokine genes,
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and reinfused into the patient following irradiation to induce an enhanced target specific
immune response to tumor sites throughout the body, b) direct local gene delivery, which
is defined as direct injection of gene vectors into target cells, and c) systemic directed
gene therapy with subsequently directed transfection of target tissues (Taneja et al.,
1995). So far, however, no single gene therapy approach has definitively improved the
health of a single one of the more 2,500 patients who have enrolled in gene therapy trials
worldwide (Anderson, 1998). The majority of gene therapy trials are still in Phase I
(evaluation of safety) or II (preliminary evaluation of efficacy), and only one reached
Phase III (evaluation of efficacy). Although there are some promising results, the
inconsistency of clinical trials, limited knowledge of in vivo gene expression and host
immune response, and lack of ideal gene delivering systems are among the main reasons
for the relative failure of gene therapy so far.
G. Gene delivery systems

A major technical obstacle for gene therapy/genetic vaccination is to find an ideal
delivery system. Many different gene-delivering systems have been applied in gene
therapy, and they can be divided into two groups: viral and non-viral vectors. Each type
of vector system has its own advantages and disadvantages. Among viral vectors,
retroviral vectors were the first ones to be applied in gene therapy trial and are the most
extensively studied vectors (Mavilio et al., 1994; Miller et al., 1989). Retroviral vectors
can integrate into host genomes and offer possible long-term gene expression. However,
retroviral vectors are unable to infect postmitotic cells, such as mature myofiber, and are
limited to carrying relatively small segments of DNA (no bigger than 7Kb). In addition,
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retroviral vectors present general disadvantages, such as the possibilities of carrying over
of adventitious microorganisms, insertional mutagenesis and/or disruption of host
geneome, and replication-competent (helper) retroviral production. Adenoviral vector is
another commonly used viral vector, and currently is the primary candidate for direct in
vivo gene delivery, but is also limited by size of DNA it can carry. Compared to the
retroviral vector, adenoviral vectors are considered safer, have a larger capacity for
foreign genes (up to 40 kb), and will not integrate into host genome. Adenovirus is also
able to infect nonreplicating cells, including skeletal muscle in vivo (Quantin et al..
1992). The drawbacks are that genes may have transient function due to lack of
integration, and there is a strong host immune reponse against the viral proteins (Miller et
al., 1993). Several other viral vectors are being explored: adeno-associated viruses,
herpesviruses, alphavirus, lentivirused, and poxviruses. None of these viral vectors is
perfect, and each is likely to have its own therapeutic advantages.
The known and unknown side effects of viral systems have encouraged the
development of nonviral delivery system (Gao et al., 1995). Compared to viral vectors,
nonviral vectors usually do not integrate into the host genome, and gene transfer
efficiency is, in general, lower when compared with viral vectors. Liposomes, which are
small spheres composed of lipid bilayers, were the first nonviral delivering vehicle, but
are considered too inefficient for gene therapy (Feigner, 1997). The DNA-lipid complex
eliminates the introduction of viral particles but demands large amount of DNA and
transfection efficiency is lower compared with viral vectors. Another shortcoming of
liposomes is that because of mismatch between liposome and plasmid (0.025-0.1 micron
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versus 2 microns), only a small portion of plasmid (less than 1%) can be encapsulated
when liposomes are synthesized in the presence of plasmids. Cationic lipids have been
applied to replace simple lipids for packaging of plasmid DNA. These new lipids, named
lipoplexes, are more variable and complicated then simple liposomes and lead to higher
gene expression level (Feigner, 1997). Combined with the use of gene gun, the gene
delivering efficiency of lipoplexes can be greatly increased (Feigner, 1997). However,
the liposomes/lipoplexes systems are generally considered much less efficient compared
to viral vector (Crystal, 1995).
As the initial route of administration for DNA vaccination, intramuscular (IM)
injection of naked DNA started to be developed as a simple and safe way to deliver
foreign genes during the late 1980’s. IM injection was first reported for transferrring
genes into skeletal muscle in vivo by direct injection of plasmid DNA without any
delivery vehicle, such as a lipid shell (Wolff et al., 1990). Intramuscular DNA delivery
has been used to express reporter genes in animal models. Several reporter genes, such
as Firefly luciferase (Wolff et al., 1990; Levy et al., 1996; Perez et al., 1996; Prigozy et
al., 1993), chloramphenicol acetyltransferase (Wolff et al., 1990; Wells, 1993; Prigozy et
al., 1993), P-galactosidase (Wolff et al., 1990; Nishi et al., 1996; Prigozy et al., 1993),
and human placental alkaline phosphatase (Perez et al., 1996) have been expressed in
adult and neonatal rat (Wolf et al., 1991), primate skeletal muscle (Jiao, et al., 1992),
cardiac muscle (Lin et al., 1990) and even in progeny (Tsukampoto et al., 1995).
Compared with viral vectors, “naked” gene transfer offers several advantages
(Levy et al., 1996; Davis et al., 1993). “Naked” DNA gene transfer strategies do not
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require dividing cells, has virtually no size limitation, and should be less likely to create
immunological problems, since plasmid DNA can be purified to homogeneity. Despite
evidence that most of the DNA remains in an unintegrated circular form, which
minimizes the risk of genomic insertional mutagenesis, expression has been shown to
persist for up to 19 months (Wolff et al., 1992). Studies have shown that in mouse
skeletal muscle, plasmid DNA transfer is more efficient than that of adenovirus and
retrovirus (Davis et al., 1993).
Seung et al. (1995) and Mauceri et al. (1996) have used viral vectors and
liposome-mediated methods to successfully delivere TNF-ot intratumorally. In
combination with radiation, the growth of murine fibrosacarcoma 1591 and human
squamous cell carcinoma SQ-20B was significantly controlled compared to radiation
alone. However, it has been noted in a number of reports and in experiments conducted
in our laboratory, that viral vectors and liposome-mediated methods have disadvantages
mentioned above for in vivo administration compared to naked DNA. Disadvantages
include immunogenicity (especially with repeated injections), potentials for random virus
integration into the host cell genome, and potential toxicity of systemically injected
cationic liposomes (Song et al., 1997; Wolff et al., 1995). Nonetheless, due to the
relatively high efficiency of gene transfer and strong gene expression, many laboratories
and pharmaceutical companies have put in great efforts to improve these methods.
H. Significance of the study
A major goal of the present study was to determine whether biologically
functional TNF-a protein would be expressed by our newly constructed plasmid, pGLl-
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TNF-a, both in cell culture and on athymic mice model. Also we evaluated the
possibility that the intratumoral administration of this DNA in combination with ionizing
radiation could inhibit progression of the aggressive, rapidly growing C6 glioma.
Multiple tests, including flow cytometry, were performed to reveal the impact of
expressed TNF-a and the combination of radiation and TNF gene therapy on tumor
bearing animals’ immune system. The results generated from this study has added
important information on aspects of gene therapy, provide a practical base for further
implementation of combination therapy on tumors with gene therapy and radiation, and
explain possible mechanisms of the interaction between TNF-a and ionizing radiation,
which would be helpful in future modification of this combination therapeutic model.
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CHAPTER TWO
MATERIALS AND METHODS

A. DNA purification
Plasmid DNA was purified by using the Plasmid Mega kit, Qiagen, Inc.
(Valencia, CA). The manufacturer’s protocol was strictly followed. A single colony was
picked from a freshly streaked selective plate and a starter culture of 2-10ml LB medium
containing the appropriate selective antibiotic (Ampicillin, 50 mg/ml) was inoculated. It
was incubated for about 8 hours at 37°C with vigorous shaking (about 300 rpm). The
starter culture 1/500 to 1/1000 then was diluted into selective Luria-Bertani (LB)
medium. For high-copy plasmids like pGLl-TNF, 2 liters medium was inoculated.
Grown at 37°C for 12-16 hours with vigorous shaking (~300 rpm), bacterial cells were
harvested by centrifugation at 6000 g for 15 min at 4°C. The bacterial pellet was re
suspended in 50 ml of Buffer PI (50 mM Tris-HCl, pH 8.0; 10 mM EDTA and 100
pg/ml Rnase A). 50 ml of Buffer P2 (200 mM NaOH, 1% SDS) was added to the
mixture, mixed gently but thoroughly by inverting 4-6 times, and then it was incubateed
at room temperature for 5 min. 50 ml of chilled Buffer P3 (3.0 M patassium acetate, pH
5.5) was then added, mixed immediately but gently by inverting 4-6 times, and incubated
on ice for 30 min. The samples were mixed several times during the incubation on ice,
followed by centrifugation at >20,000 x g for 30 min at 4°C. The supernatant containing
plasmid DNA was removed promptly. The supernatant was re-centrifuged at >20,000 x g
for 15 min at 4°C. Supernatant containing plasmid DNA was removed promptly.
Alternatively, the sample can be filtered over a prewetted, folded paper filter. A
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QIAGEN-tip 2500 was equilibrated by applying 35ml Buffer QBT (750 mM NaCl; 50
mM MOPS, pH 7.0; 15% ethanol; 0.15% Triton X-100), and allow the column to empty
by gravity flow. Apply the supernatant to the QIAGEN-tip and allow it to enter the resin
by gravity flow. The QIAGEN-tip was washed with 2 x 100 ml Buffer QC (1.0 M NaCl;
50 mM MOPS, pH 7.0; 15% ethanol). DNA was eluted out with 35 ml Buffer QF (1.25
M NaCl; 50 mM Tris-HCl, pH 8.5; 15% ethanol). DNA was then precipitated by adding
24.5 ml room temperature isopropanol to the eluted DNA, then mixed and centrifuged
immediately at >15,000 x g for 30 min at 4°C. The supernatant was carefully decanted.
DNA pellet was washed with 7 ml of room temperature 70% ethanol, and centrifuged at
>15,000 x g for 10 min. The supernatant was carefully decanted without disturbing the
pellet. The pellet was allowed to air-dry for 10-20 min, and the DNA was re-dissolved in
a suitable volume of TE buffer (10 mM Tris-HCl, pH 8.0; 1 mM EDTA).
B. Purification of plasmid DNA by equilibrium centrifugation in CsCl-Ethidium
Bromide gradients
The volume of semi-purified DNA solution was measured. For every milliliter,
1.0 g of solid CsCl was added. The solution was warmed to 30°C to facilitate the
dissolution of the salt and was mixed gently until the salt was dissolved. A 0.8 ml aliquot
of ethidium bromide (10 mg/ml in water) was added for every 10 ml of the DNA/CsCl
solution. The ethidium bromide solution (which floats to the surface) was immediately
mixed with the denser DNA/CsCl solution. The final density of the solution was 1.55
g/ml and the concentration of ethidium bromide should be approximately 740 pg/ml.
The solution was centrifuged at 8,000 rpm for 5 minutes at room temperature in a Sorvall
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SS34 rotor. A furry mixture consisted of complexes formed between the ethidium
bromide and bacterial proteins were floated to the top. Using a disposable syringe fitted
with a large-gauge needed; the clear, red solution under the mixture was transferred to a
tube (Beckman Quick-Seal) suitable for centrifugation in a Beckman vertical Ti65 rotor.
The remainder of the tube was filled with light paraffin oil and the tube was sealed. The
density gradients were centrifuged at 60,000 rpm for 24 hr at 20°C. Two bands of DNA,
located in the center of the gradient, were visible in ordinary light. The lower band
consisted of closed circular plasmid DNA. The outside of the tube was carefully wiped
with alcohol to remove any grease or oil, a syringe was used to punch a hole in the top of
the tube to allow air flow, an 18-gauge hypodermic needle (beveled side up) was inserted
into the tube. With the beveled side of the needle positioned just below the plasmid band
and parallel to it, the band containing the circular DNA was carefully collected into a
plastic tube. An equal volume of 1-butanol saturated with water was added to the tube
with collected DNA solution and the two phases were mixed by vortexing. The mixture
was centrifuged at 1500 rpm for 3 minutes at room temperature and the lower aqueous
phase was transferred to a clean plastic tube. The extraction steps were repeated until all
the pink color had disappeared from both the aqueous and organic phases. The CsCl was
removed from the DNA solution by dialysis for 24 hours against several changes of TE
(pH 8.0). The optical density (OD) of the final solution was measured using a Beckman
DU-640 spectrophotometer (Fullerton, CA) at wavelength of 260 and 280 nm and the
concentration of the purified plasmid was calculated.
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C. Cell lines
The rat C6 nitrosourea-induced glioma cell line, originally established by Benda
et al. (1968), was obtained from the American Type Culture Collection (ATCC;
Rockville, MD). This cell line was selected for the present study because it has many of
the pathological and growth characteristics observed with human gliomas (Auer et al.,
1981; Earle et al., 1983). The cells were cultured in Dulbecco’s minimal essential
medium (DMEM; Irvine Scientific, Santa Ana, CA) supplemented with 10% heatinactivated bovine calf serum (BCS; Hyclone Laboratories, Logan, UT), 100 pg/ml
fungizone (E.R. Squibb & Sons, Princeton, NJ), and 50 pg/ml gentamicin (Sigma
Chemical Co., St. Louis, MO). The cells were incubated at 37°C in 5% CO2 until near
confluence, harvested with 0.25% trypsin solution, washed, counted and adjusted to the
appropriate concentrations for the in vitro and in vivo experiments.
Mouse L929 cells were also obtained from ATCC. Sanford et al. (1948)
established the cell line in March 1948. Parent L strains were derived from normal
subcutaneous areolar and adipose tissue of a C3H/An mouse. The L929 cells were
cultured in DMEM supplemented with 10% heat-inactivated BCS (Hyclone), lOOpg/ml
fungizone (E.B Squibb & Sons), and 50pg/ml gentamicin (Sigma). This cell line is
known for being sensitive to the cytotoxic effect of TNF-a and has been frequently used
to test for the biological activity of the cytokine.
D. PGLl-TNF-a construction and purification
The human recombinant TNF-a coding sequence in plasmid pUC18 was
purchased from R&D Systems, Inc. (Minneapolis, MN). The plasmid was digested with
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restriction enzymes, EcoRI at the 3’ end, blunted by Klenow, and then digested by
Hindlll. After the coding sequence was excised, the purified TNF-a fragment was ligated
into the polylinker region of plasmid pWS4, a universal eukaryotic gene expression
vector originally developed by Sheay et al. (1993) using T4 ligase. The pWS4 plasmid
was kindly provided by Dr. Istvan Fodor of the Center for Molecular Biology and Gene
Therapy, Loma Linda University. The polylinker region was deleted to enhance gene
expression. This resulted in a modified pWS4 containing the TNF-a sequence. The
pWS4, as well as the final end product, contains a cytomegalovirus (CMV) promoter, an
adenovirus tripartite leader (Avtl) sequence, a Poly A sequence and an ampicillin
resistance gene. Proper orientation of the TNF-a coding sequence was confirmed by
restriction enzyme digestion and gel electrophoresis. Large amounts of pGLl-TNF-a for
later experiments were obtained by transformation into competent E. coli (strain DHa5)
cultured in LB broth medium; the DNA was purified using the Plasmid Mega kit
(Qiagen). The purification was performed by strictly following the manufacturer’s
protocol.
E. In vitro transfection of C6 cells
Transfection reagent, a cationic polyamine (Superfect™), was purchased from
Qiagen, Inc., and the C6 cells were transfected following the company’s protocol.
Briefly, the day before transfection, 4 x ICf C6 cells per well were seeded in 35-mm 6well plates in 2 ml of DMEM. The cells were at 70% confluence on the day of
transfection. The C6 cells were incubated at 37°C and 5% CCL in an incubator. An
aliquot of 5 pg of DNA was dissolved in TE, pH 8.0 (DNA concentration: 1.0-3.8mg/ml)
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with DMEM containing serum, proteins, or antibiotics to a total volume of 150 pi. The
solution was mixed and spun down for a few seconds to remove drops from the top of the
tube. The SuperFect™ Transfection Reagent (15 pi) was added to the DNA solution and
mixed by pipetting up and down 5 times, or by vortexing for 10 seconds. The samples
were incubated for 5-10 minutes at room temperature (20-25°C) to allow complex
formation. During complex formation, the DMEM was gently aspirated from the wells
containing C6 cells, and the cells were washed once with 2 ml of phosphate buffered
saline (PBS). Complete DMEM (1 ml; containing serum and antibiotics) was added to
the reaction tube containing the transfection complexes. The solution was mixed by
pipetting up and down twice, and the total volume was immediately transferred to the
cells in the plates. The cells were incubated with the complexes for 3 hours at 37°C in
5% CCF. The medium containing the remaining complexes was removed from the cells
by gentle aspiration, and the cells were washed once with 2 ml of PBS. New cell growth
medium (containing serum and antibiotics) was added. The cells were harvested and
assays for gene expression were performed after an appropriate incubation time.
F. Assay for TNF-a protein in conditional medium
Aliquots of conditioned medium (CM) from C6 cells transfected with at pGLlTNF-a/polyamine were collected at different time intervals and subjected to
measurement using a solid-phase enzyme-linked immunosorbent assay (ELISA) for
TNF-a (Quantikine™ kit, R & D Systems). Supernatants from C6 cells treated with
pGLl-TNF-a without transfection reagent were included; human recombinant TNF-a
protein (R & D Systems) was added to some of 3 wells (without cells) at a concentration
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of 2500 units/ml as a positive control. The assay was performed according to the
manufacturer’s instructions. Briefly, duplicate aliquots of the samples were dispensed
into wells of 96-well microtiter plates pre-coated with monoclonal antibody specific for
human TNF-a. If the cytokine was present, it was captured and immobilized by the
antibody. After incubation and washing, a second TNF-a-specific polyclonal antibody
conjugated to horseradish peroxidase was added and the plates were re-incubated. After
washing again, the substrate (tetramethylbenzidine) for the enzyme was added to each
well. Color development was stopped with a stop solution consisting of acids and the
450nm absorbance in each well was quantitated in an automated MRX Microplate Reader
(Model Fluorite 1000; Dynex Technologies, Inc., Chantilly, VA). The concentrations of
TNF-a in the test samples were interpolated from the standard curve. The sensitivity of
this assay is 4.4 pg (0.48 unit)/ml.
G. Activity of TNF-a protein expressed by pGLl-TNF-a transfected C6 cells
L929 cells (ATCC), were cultured in complete DMEM at 5 X 105 cells/2 ml/well
in 35 mm, 6-well plates until 60-80% confluent. The medium was removed from the
L929 cells, aliquots (1 ml/ well) of CM from transfected C6 cells were added and cell
viability was determined at various time intervals thereafter using a standard trypan blue
exclusion method. Briefly, cells were washed and diluted in 1 ml PBS, 10 pi of trypan
blue solution were added and mixed well, only dead cells will be stained as blue. A small
volume of cell suspension was then subjected to counting under light microscope. CM
from nontransfected C6 cells and human TNF-a protein were included as controls. The

27

L929 cell line, one of the first to be established in vitro, is a mouse fibroblast line that is
known to be susceptable to the cytocidal effects of TNF-a.

H. Immunofluorescence staining and quantitation of TNF-a receptors by laser
scanning cytometry (LSC)
Cultured C6 cells were grown on sterile glass cover slips overnight at 37°C. At
time of staining, the cover slips were rinsed briefly with PBS twice, then fixed for 5-20
min in -10°C enthnol. Specimens were incubated with 10% normal serum in PBS for 20
min to suppress non-specific binding of IgG. This step and all subsequent incubations
were carried out at room temperature in a humidified chamber. Suction was used to
remove reagents after each step, and drying of the specimens between steps were
avoided. Sufficient reagents were used to cover the specimen and later samples were
washed with PBS. Goat anti-murine TNF-a P55 and P75 receptor polyclonal antibodies
(Santa Cruz Biotechnology, Santa Cruz, CA; IgG class) diluted to 5pg/ml in PBS
containing 5% bovine serum albumin were added as the primary antibodies. These
antibodies react with TNF-a receptors on cells of both mouse and rat origin. The cells
were incubated with primary antibodies at room temperature for 2 hr, washed with three
changes of PBS, 5 min each. Then cells were incubated with a mixture of propidium
iodide and fluorescein isothiocyanate (FITC)-labelled rat anti-goat IgG monoclonal
antibody (secondary antibody) for TNF-a for 1.5 hr in dark at room temperature. After
the final wash with PBS, coverslips were mounted with aqueous mounting medium. The
slides were then examined by using a fluorescence microscope.
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The C6 and L929 cells were grown on sterile coverslips until 60% confluency and
then fixed with ice cold 100% ethanol. The staining procedure was described as above.
The coverslips were mounted with Cytoseal™ 60 (Stephens Scientific, Riverdale, NJ) on
slides for analysis of green fluorescence intensity using a microscope-based
multiparameter laser scanning cytometer (Compucyte Corp., Cambridge, MA) interfaced
with a Pentium 100 processor and Wincyte™ software. Fluorescence from stained cells
was emitted upon laser beam excitation and was collected by multiple sorters for
computer analysis. Negative controls were treated in the same manner, but without the
primary antibodies. The scanning cytometer was set to identify 2,000 cells by red
propidium iodide (final concentration of 5 pl/ml) staining of cell nuclei. A fluorescence
intensity contour level was then determined to include the projected cell area, (centered
on each nucleus) which is positive for green fluorescence. The integral green
fluorescence was determined for each cell and reported as a cell frequency versus
fluorescence intensity histogram.
I. Animals, tumor induction and tumor volume
Athymic mice (outbred background, male, nu/nu) were purchased from Charles
River Breeding Laboratories, Inc. (Wilmington, MA) at 5-6 weeks of age and housed in
self-contained filter-top cages (3-4 mice/cage) in a room controlled for temperature,
humidity, and a 12 hr day-night cycle. Autoclaved bedding, food, and water were
provided upon arrival and at every cage change. The animals were allowed to
acclimatize for 2 weeks prior to experimentation. Rapid CO2 asphyxiation was
performed at the end of the study in compliance with the NIH Guide for the Care and
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Use of Laboratory’ Animals. The study was approved by our institutional Animal
Research Committee. The C6 tumor cells were harvested, washed, counted, adjusted to a
concentration of 2.5 X 106 cells/ml in PBS and injected subcutaneously (SC) in the right
hind flank (0.2ml or 5 X lO3 cells/mouse). The animals were observed daily until a
palpable mass appeared. Thereafter the dimensions of each tumor were measured with
vernier calipers and volumes were calculated using the following formula: tumor volume
(mm3) = (H X W X L)/2, where H = height, W = width, and L = length of the tumor.
J. Radiation Specifications and Procedures
1. Gamma radiation.
Cells and tumors in the appropriate experiments were irradiated with y-rays
(photons) using an Eldorado Model ‘G’ gamma radiation machine (Atomic Energy of
Canada, Ltd., Commercial Products Division, Ottawa, Canada) containing a 60cobalt
(60Co) source with a vertical beam projected to a 20 X 20 cm field size. The radiation
instrument is located within the Animal Care Facility of the Loma Linda University
Medical Center. For C6 cells transfected with pGLl-TNF-cc, radiation were given at 2, 4,
6, 8, and lOGy, with each dose delivered in a single treatment fraction. Prior to tumor
irradiation, mice were lightly anesthetized by intraperitoneal (IP) injection of a
combination of ketamine (80mg/kg body weight) and xylazine (5.2 mg/kg body weight).
Mice not scheduled for irradiation were also anesthetized to equalize the stress factor. A
total volume of about 0.1ml was injected per mouse. The anesthetic and masking tape on
the extended tumor-bearing legs ensured immobilization during irradiation. Tumors were
irradiated with 2Gy for 3 fractions, giving a total dose of 6Gy per tumor. The dose of
2Gy/fraction was selected because it can be safely delivered to small volumes and is a
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common dose/fraction employed in treatment of cancer patients. The dose rate was about
0.32Gy/min. Multiple mice (up to 8 mice/irradiation procedure) were placed within the
exposure field for simultaneous irradiation. Since Lipowitz metal alloy blocks of 3 inch
thickness were used to shield the normal tissues of the animals, only the tumor and the
underlying leg tissue was significantly irradiated; the non-irradiated portion of the animal
bodies received only 3% of the delivered dose. A 0.5 cm thick bolus which enables was
placed on top of each tumor during irradiation to achieve full electronic equilibrium.
Calibration of the dose was performed with a Capintec Model PR06-G cylindrical
thimble ionization chamber according to the National Institute of Standards and
Technology (NIST).
2. Proton radiation.
Irradiation by proton of tumors was performed in the Proton Therapy Facility,
located within the Loma Linda University Medical Center, close to the animal quarters,
thus minimized animal transportation. The proton accelerator is a 70-250 MeV
synchrotron and is capable of rapid, precise energy change and continuous, slow, uniform
beam extraction. The system transports the beam through a vacuum tube to the treatment
rooms or the proton research room shredded and focussed via large electromagnets and is
under computerized control. In the present study, the proton accelerator specifications
were adjusted to duplicate as closely as possible the 60Co irradiation conditions (e.g.,
radiation field, dose rate). Mice were anesthetized prior to tumor irradiation, as described
in the above section. The beam was collimated to project a 15 X 15 cm field size where
the tumor bearing thigh of the mice were placed in. Tumors were irradiated with protons
at 250 MeV energy and at spread-out Bragg peak; the tumor surface was at the center of
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the modulated beam. A Leipowitz metal alloy shield protected the bodies of the animals;
no primary protons can penetrate this shield. Equal dose distribution was achieved by
placing a 29.4cm HEO-equivalent polystyrene block between the beam and the tumors. A
dose of 2Gy/fraction was delivered three times over period of 9 days, resulting in a total
radiation dose of 6Gy/tumor. Protons were delivered from the accelerator in 0.3 second
pulses every 2.2 seconds, giving an average dose rate of ~0.9Gy/min. Tumors in up to 8
mice were irradiated simultaneously. Calibration of the dose was performed by placing a
Memorial parallel plate ionization changer, according to the NIST standard, between the
alloy blocks at the same position as the tumors during irradiation.
k. 60Co irradiation of transfected C6 cells
5 pg of pGLl-TNF-a was transfected into 1 x ICE C6 cells by using 15 pg of
SuperFect1M transfection reagent at the beginning of experiment. One day after
transfection, the cells were dispensed into wells of 96-well microtiter plates at
approximately 5 x 103 /well and incubated for 24 hours at 37°C in 5% CO2. The cells
were then subjected to 60Co irradiation at doses of 2, 4, 6, 8, and 10 Gy, each delivered in
a single fraction. The cells were pulse-labelled with 3H-TdR during the last 4 hours of
incubation prior to harvesting in an automated cell harvester (Brandel). The level of 3HTdR incorporation into cell DNA was quantitated at timed intervals for a total of 4 days.
L. Phase I in vivo study: Expression of TNF-a protein in C6 tumor xenografts
injected with pGLl-TNF-a
5 x lO5 C6 cells were injected SC into the right thigh of each athymic mouse.
Seven days after injection, when tumors had reached a palpable level, 15 pg, 150 pg, and
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450 |_ig of pGLl-TNF-cc was injected intratumorally in a single injection and a total
volume of 225 pi. The same volume of PBS and 450 pg ofpWS4 (the parental plasmid)
were administered in the same manner to control groups. Subsets of animals from each
group were euthanized at 18hr, 48hr and 168hr (7 days) after treatment. Tumor volumes
were measured at each time of euthanasia. Tumors were excised and frozen in liquid
nitrogen for later assays of TNF-a expression. Peripheral blood was collected by cardiac
puncture for flow cytometry analysis and TNF-a quantitation.
M. Phase II in vivo study: Effect of pGLl-TNF-a, with and without transfection
reagent, on C6 tumors in combination with 60Co radiation
On day 9 after C6 cell implantation, athymic mice were assigned to the following
groups (n = 4): a) no tumor or normal control, b) nontreated tumor control, c) pGLlTNF-a, c) pGLl-TNF-a/SuperFect TM , d) pGLl-TNF-a + 60Co radiation, e) pGLl-TNFa/SuperFect™ + 60Co radiation. At this time, tumors were well-established and palpable
in all animals receiving C6 cells. An intratumoral injection of pGLl-TNF-a (with and
without the polyamine transfection reagent) was administered at a dose of 50 pl/injection
+/- 15 pg SuperFect TM using a lOpl Hamilton syringe with a 1/2 inch needle. The
solution was injected in a single location, approximately in the center of the tumor mass.
Sixteen to 18 hours thereafter, the mice were lightly anesthetized and tumors were
irradiated with 2 Gy 60Co. Each modality was delivered three times [pGLl-TNF-a (+/SuperFect™) on days 9, 13, and 16; radiation on days 10, 14, and 17]. The animals were
euthanized when mean tumor volume in the nontreated tumor control group reached
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approximately 2,000mm3 (17 days after C6 cell implantation). Blood and spleens were
collected for in vitro assays described below.

N. Phase III in vivo study: Effect of different doses of pGLl-TNF-ot on C6 tumors
in combination with 60Cobalt radiation
This phase was performed essentially as described above, except that three
different total doses of pGLl-TNF-oc were injected intratumorally: 15 pg (5pg x 3
injections), 150 pg (50 pg x 3 injections) and 450 pg (150 pg x 3 injections). Polyamine
transfections reagent (SuperFect™) was not used in this study. The groups were: a) no
tumor or normal control, b) nontreated tumor control, c) pGLl-TNF-a at 150 pg, d) 60Co
radiation, e) pWS4 at 150 pg + 60Co radiation, f) pGLl-TNF-a at 15 pg + 60Co radiation,
g) pGLl-TNF-a at 150 pg + 60Co radiation, and h) pGLl-TNF-a at 450 pg + 60Co
radiation. There were 5-6 mice/group. The animals were euthanized 2 days after the last
treatment and the blood and spleens were collected for in vitro assays described below.
O. Phase IV in vivo study. Effect of pGLl-TNF-a on C6 tumors in combination
with proton radiation
This experiment was performed as described above, except that treatments were
initiated 3 days after C6 cell injection, before tumor masses were visible and had reached
palpable size. Irradiation of tumors was performed in the proton research room using a
horizontal beam line. The groups were as follows (n = 8) : a) no tumor or normal control,
b) nontreated tumor control, c) proton radiation, d) pGLl-TNF-a at 150 pg, e) pWS4 at
150 pg, f) pWS4 at 150 pg + proton radiation, g) pGLl-TNF-a at 150 pg + proton
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radiation. The animals were euthanized when mean tumor volume in the nontreated
tumor control group reached approximately 2,000mm3. Blood and spleens were collected
for in vitro assays described below.
P. Phase V in vivo study: Comparison of pGLl-TNF-a effect on C6 tumors in
combination with 60Co and proton radiation
This study was performed as described in phase I, except that intratumoral
injection of pGLl-TNF-a (150pg in 3 injections) was initiated on day 7 after C6 cell
implantation, when palpable tumor was observed. The groups (n = 5-7 mice/group) were:
a) no tumor or normal control, b) nontreated tumor control, c) 60Co radiation, d) proton
radiation, e) pGLl-TNF-a at 150 pg, f) pGLl-TNF-a at 150 pg + 60Co radiation, g)
pGLl-TNF-a at 150 pg + proton radiation. Blood and spleen samples were collected at
time of euthanasia for further analyses as described below.
Q. Spontaneous blastogenesis assay
A 50 pi aliquot of whole blood from each test animal was dispensed into wells of
96-well flat-bottom microtiter plates. RPMI 1640 culture medium (150 pi) and 3Hthymidine (3H-TdR; specific acitivity = 46 Ci/mmol; ICN Radiochemicals, Irvine, CA)
containing 1 pCi/50 pi was then immediately added to each well. Samples from each
animal were tested in triplicate. The plates were incubated for 4 hours at 37°C with 5%
CO2. After incubation, harvest the incubated samples to filter paper using automated
multiple sample harvester (Brandel, Gaithersburg, MD). Sample discs were cut out from
the filter paper and put into scintillation vials; 2ml of scintillation fluid was added into
each sample vial, samples were then subjected to count for the incorporated radioactivity
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using beta scintillation counter (Beckman, Inc., Fullerton, CA). The results are expressed
as disintegrations per minute (dpm).
R. LPS induced splenocyte proliferation assay
The sequence of plate design for the 96-well plates to be used was recorded to trace
exact order of different samples for later anlalysis. Spleens were excised from euthanized
animals in a sterile fashion, smashed in 2ml of RPMI 1640 medium using autoclaved
applicator sticks. The cells were centrifuged at 2000 rpm for 5 min, and the supernatant
was discarded. Cold ACK lysing buffer (0.01M KHCO3/0.154 M NH4C1/0.01 mM
EDTA) was added at 1-2 ml to remove erythrocytes, the remaining cells were re
suspended by mixing well and incubated at 4°C in the refrigerator for 5 min. Complete
RPMI medium (with antibiotic and serum) at 1 ml/tube was added; the cells were mixed
well and centrifuged at 2000 rpm for 5 min; the supernatant was discarded. The cells
were counted and diluted with complete RPMI 1640 medium to a final concentration 2 x
106 cells/ml. Aliquots of the cell suspensions were dispensed into microtiter plate wells
(0.1 ml/well) and 0.1 ml of lipopolysaccharide (LPS; from E. coli serotype 0111 :B4,
Sigma Chemicals, Inc, St. Louis, MO) was added to each well. The LPS was pre-titrated
for maximum response. Each sample was dispensed in triplicate. Triplicate control wells
for each sample received 0.1 ml of medium with no LPS. The plates were incubated for
72 hr at 37°C with 5% CO2. 3H-TdR was added at lpCi/50pl/well and the plates were
incubated for 4 hours at 37°C with 5% CO2. Cell harvesting and quantitation of 3H-TdR
incorporation into cell DNA was performed as described in the spontaneous blastogenesis
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assay. The obtained dpm were used to calculate a stimulation index (SI) as follows: SI =
[dpm (w/ LPS) - dpm (w/o LPS)]/ dpm (w/o LPS).
S. Relative spleen weights and spleen and blood leukocyte counts
At the time of euthanasia, the animal were weighed, the spleens were removed
and weighed. The relative spleen weight (RSW) was calculated as follows: RSW =
weight of spleen /animal body weight. To determine leukocyte concentration in
peripheral blood, erythrocytes were lysed by using the Unopette Microcollection System
(Becton Dickinson Co., Rutherford, NJ) and then counted manually with a
hemocytometer. Spleens were placed in 1 ml of sterile RMPI 1640 medium and
homogenized with sterile applicator sticks. Erythrocytes were lysed by addition of 1 ml
of ammonium-chloride-potassium (ACK) lysing buffer followed by 5 minutes of
incubation at 4°C. the cells were centrifuged for 10 minutes, washed and suspended in 2
ml of RPMI 1640 medium and counted manually with hemocytometer using trypan blue
exclusion method.
T. Flow cytometry analysis of spleen and blood lymphocyte populations
Immunophenotyping of peripheral blood and spleen samples was carried out to
quantitate lymphocyte populations using a FACSCalibur™ 4-channel dual laser flow
cytometer (Becton Dickinson,Inc, San Jose,CA). Multiparameter flow cytometry was
used to define unique subpopulations within the lymphocyte population using side scatter
(SSC-cell granularity) versus CD45 (leukocyte common antigen), and several antibodies
labelled with a different-colored fluorochrome. No other analysis system can obtain this
information as rapidly on large numbers of cells while “sorting" the unique population of
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interest. By using more than one antibody simultaneously it was possible to perform
single-antibody histogram analysis and multiparameter analysis. Multiple use of
antibodies, however, provided the opportunity to resolve unique cell populations that
cannot otherwise be identified.
“Cell gating” was used to specifically gate the cells of interest first - in this case the
lymphocytes - and then display the other parameters within the gated lymphocyte
population. In this study the mouse leukocytes were resolved using CD45 to initially gate
the lymphocytes and then combined with 4-5 other antibodies such as anti-CD3, CD4,
CDS, B220 and Pan-NK. All MAb, labeled with fluorescein isothiocyanate (FITC),
phycoerythrin (PE), allophycocyanin (APC), or peridinin chlorophyll protein (PerCP),
were purchased from Pharmingen (San Diego, CA). A custom-conjugate specially
designed for this study and other similar studies was developed by Pharmingen using the
above indicated antibodies:
CD3*FITC/CD8*PE/CD45*PerCP/CD4*APC
CD3*FITC/Pan-NK*PE/CD45*PerCP/B220*APC
The labelled MAb were directed against the following markers:CD45 - common
leucocyte marker, binds to all leukocytes with varying brightness; CD3 - T cell receptorassociated complex present on all mature T lymphocytes.; CD4 - protein on T
helper/inducer (Th) cells; CDS - protein on T cytotoxic/suppressor (Tc) cells; B220 protein on B lymphocytes; and Pan-NK - protein on NK cells.
For this study the mouse "Lyse/No Wash Staining Protocol” - developed by
Pharmingen was used to stain the blood and spleen samples. The lysing buffer used for
this protocol was pre-warmed in a 37-40°C waterbath. This protocol used a 2-tube panel.
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An aliquot (20 ql) of each custom antibody mixture was dispensed into a separate tube.
For the peripheral blood and spleen samples, 50 pi aliquots of the undiluted blood sample
and resuspended filtered spleen sample were dispensed into the 2 tubes (precounted white
blood cells). The tubes were vortexed and incubated for 20 minutes in the dark at room
temperature. Then 450 pi of the lysing buffer (prewarmed) was added to each tube. The
tubes were then vortexed, capped, and incubated in a 37-40°C water bath for 20 minutes.
The samples were then placed on ice until acquisition in the the flow cytometer.
Acquisition of 10,000 lymphocyte events/tube was performed on the
FACSCalibur™ with the threshold trigger on FL3 using the Lyse/No Wash FACSComp
Settings. Stained samples were acquired within 6 hours of staining. FITC, PE, and
PerCP are all excited by the argon laser (the blue laser - 488 nm) whereas APC is excited
by the red laser within the flow cytometer. Multiparameter analysis was performed using
CellQuest software Version 3.1 (Becton Dickinson). Purity calculations (based on sum
of percentages of B220, CD4, CDS and Pan-NK positive cells) of the gated lymphocytes
in each sample were used to convert the raw percentages of T, Th, Tc, B and Pan-NK
populations to normalized percentages. To obtain absolute counts for each lymphocyte
population, the following formula was used:
Absolute counts/ml = leukocyte counts/ml x normalized percentage.
U. Hematological analysis
Whole blood samples were evaluated using the ABC Vet Hematology Analyzer (Heska
Corporation, Waukesha, WI) which was specifically programmed to analyze
hematological parameters in the mouse. A 12 pi sample was analyzed per animal. The
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measurements included red blood cell count (RBC;106 /fil), hemoglobin concentration
(Hgb; g/dl), hematocrit levels (Hct; % volume of whole blood composed of RBC), mean
corpuscular volume (MCV; mean volume per RBC in femtoliters), mean corpuscular
hemoglobin (MCH; mean weight of hemoglobin per RBC in pg), mean corpuscular
hemoglobin concentrations (MCHC; concentration of hemoglobin per RBC in g/dl), and
platelet (Pit; 109/pl) counts. The MCV was calculated by dividing the Hct by the RBC
count and multiplying by 10. MCH was calculated by dividing the Hgb concentration by
the RBC count and multiplying by 10. MCHC was calculated by dividing the Hgb
concentration by the Hct and multiplying by 100.
V. Statistical analysis
The data were assessed using one-way analysis of variance (ANOVA), Tukey’s
HSD (honestly significantly difference test), and the nonparametric Kruskal-Wallis test.
A p value of <0.05 was taken to indicate significant differences. These analyses were
performed using SigmaStat software version 2.03 (SPSS, Inc., Chicago, IL).
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CHAPTER 3
RESULTS

A. Construction of TNF-a expressing plasmid pGLl-TNF-a
Plasmid pGLl-TNF-a was successfully constructed as described in Material and
Method chapter. By restriction enzyme digestion and gel electrophoresis, it was proved
that the TNF-a coding sequence was in the right orientation under the control of the
CMV promoter. Large amount of the plasmid was purified using Qiagen Maxiprep,
Megaprep products and CsCl-Ethidium Bromide gradients method as described for later
studies. A schematic representation of the pGLl-TNF plasmid construction was shown
in Figure 3.
B. In vitro study of pGLl-TNF-a’s effect on tumor cells with and without 60Co
radiation
1. TNF-a expression by transfected C6 cells
The vector plasmid pGLl-TNF-a was capable of producing relatively high levels
of human TNF-a protein following transfection into C6 rat gliomas. In vitro experiments
using different ratios of pGLl-TNF-a and the transfection reagent resulted in similar
levels of TNF-a expression by C6 cells. The expression of accumulated TNF-a was
detectable up to 7 days and averaged 0.4 ng (approximately 44 units) of TNF-a/ml of
supernatant from 1 x lO5 cells. By day 7, the cultured cells reached 100% confluency,
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Figure 3. Scheme for plasmid pGLl-TNF-a construction.
CMV:
cytomegalovirus promoter; Avtl: adenovirus tripartite leader sequence; Poly A:
polyadenylate sequence; amp: ampicillin resistance gene; ORI: origin of replication in
E. coli; Hindlll and EccRl\ restriction sites used to insert the TNF-oc gene.

42

43

started to detach from the supporting matrix and lost their viability. The sampling and
measurement was stopped. Data from a representative experiment are shown in Figure 4.
The transfection and quantitation of TNF-a were repeated three times and similar results
were achieved each time. High optical densities were obtained from positive control
wells containing only medium and recombinant human TNF-a protein.
2. Effect of transfected C6 cell supernatant on L929 cell viability
Table 1 presents the results of a representative experiment to determine biological
activity of the TNF-a protein secreted by transfected C6 cells. The data showed that
supernatant from C6 cells transfected with the pGLl-TNF-a/transfection reagent
complex reduced L929 viability by 61%, whereas the viability was not affected by
supernatants from C6 cells to which only the plasmid DNA (without transfection reagent)
had been added.

3. TNF-a receptor quantitation by LSC
To determine whether the different responses of L929 and C6 cells could be
influenced by TNF-a receptor number or distribution, we performed a semi-quantitative
analysis of receptor abundance by laser scanning cytometry. This technique illuminates
cells on slides or cover-slips in a raster scanned pattern with an excitation laser using
epifluorescence illumination and quantifies emission by photo-multiplier tubes.
Photographs of C6 cells stained for membrane TNF-a receptor I (P55) and receptor 2
(P75) were shown in Figure 5. In Figure 6, histograms generated from laser scanning
cytometry revealed the intensity of P55 and P75 TNF-a receptors on C6 and L929 cells.
Approximately 2000 cells were scanned in each sample’s analysis. On L929 cells, both
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Figure 4. TNF-oc expression in pGLl-TNF-a transfected C6 glioma cells.
C6
cells (4 x 105) were seeded in 35-mm dishes and transfected with pGLl-TNF-a
complexed to SuperFect™ transfection reagent. Aliquots of cell culture medium (500 pi)
were taken at various time intervals and tested for human TNF protein concentration by
ELISA using monoclonal antibodies specific for the cytokine. The concentrations at each
time point were obtained from standard curves.
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Table 1. Effect of conditioned medium from pGLl-TNF-a/ polyamine transfected C6
cells on L929 cell viability
Number of viable L929 cells (1 x 105/ml) with time3
Media

1

Day: 0

2

3

DMEMb

5.0

9.0 +/- 0.8

16.1 +/- 1.4

24.3 +/-2.0

DMEM / TNF-ac

5.0

2.4 +/- 0.4e

3.8 +/- 0.5e

8.0 +/- 1.3e

C6 CMd

5.0

9.5 +/- 0.8

16.2+/- 1.3

23.6+/-0.9

Transfected C6 CM

5.0

3.3 +/-0.5e

6.1 +/- 0.9e

10.5 +/- 0.8e

aCell viability was determined by the trypan blue exclusion method.
bDMEM: complete Dulbecco’s minimal essential medium.
CDMEM with human recombinant TNF-a protein at 20ng/ml.
dCM: conditioned medium.
eSignificantly lower than DMEM and C6 CM groups (p<0.05).
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Figure 5. Photographs of TNF receptors expressed on C6 glioma cells.
C6
cells were grown on coverslips and incubated with primary goat polyclonal antibodies
against murine TNF receptors for 2 hr. cells were then washed with PBS three times,
incubated with a mixture of propidium iodide and fluorescein isothiocyanate (FITC)labelled rat anti-goat IgG secondary monoclonal antibody for TNF-a for 1.5 hr. Cells
were then washed, mounted and subjected to observation. Green fluorescence emitted
from stained TNF receptors. (Magnification: x 680) A. TNF receptor p55 (exposure
time: 1 1/3 min); B. TNF receptor p75 (exposure time: 2 2/3 min).
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Figure 6. Histograms of fluorescence intensity of TNF-a receptors on C6 and L929
cells. Cells were cultured on coverslips, fixed with alcohol, and incubated with primary
goat polyclonal antibodies against the P55 (blue outline) and P75 (red line) receptors.
FITC anti-goat antibody was used as the secondary antiobody. The cells (approximately
2000/coverslip) were analyzed by laser scanning cytometry. Identical contouring and
PMT (photomultiplier tube) gain values were used for both cell types, which were
analyzed in a single experimental session to assure equivalence of fluorescence intensity
units.
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P55 and P75 receptors were detected at similar levels, whereas C6 cells expressed
significantly higher levels of P55 than P75 cells. The overall higher fluorescence
intensity on L929 cells compared with C6 cells may be partially due to the larger size of
L929 cells.
4. Effect ofpGLl-TNF-a on transfected C6 cells in combination with 60Co radiation
Equal quantities (5 pg) of pGLl-TNF-a were transfected to C6 cells by using the
SuperFect™ transfection agent. Twenty-four hr after the transfection, the cells were
subjected to 60Co irradiation at doses of 2, 4, 6, 8, 10 Gy respectively. Tumor cell growth
was measured by the 3H-thymidine uptake method for 4 days. As shown in Figure 7, the
polyamine transfection agent treated C6 cells had the most inhibited growth, compared to
cells without any treatment and cells treated with pGLl-TNF-oc only. The differences are
significant. The polyamine facilitated pGLl-TNF-a transfected cells’ growth was
significantly inhibited compared with the two control groups respectively, but when
compared with the polyamine treated cells, the inhibition effect was similar, if not less
than. The same observation was obtained when all groups were combined with all
different doses of 60Co radiation.
C. In vivo studies: Effect of pGLl-TNF-a and radiation on C6 tumor xenograft
1. Phase / in vivo study:

Expression of TNF-a protein in C6 tumor xenograft

a. TNF-q expression by pGLl-TNF-a in C6 tumor bearing athymic mice
C6 cells were injected subcutaneously into the right thigh of athymic mice. 7
days after the injection, the tumor reached a palpable level. 15pg, 150pg and 450pg of
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Figure 7. Effect of combination of pGLl-TNF-a and cobalt radiation on C6 glioma
cell growth in cell culture. C6 cells were seeded in 6-well culture plates. PGLl-TNF-a
was transfected to C6 cells with the facilitation of SuperFect™, followed 40 - 42 hr later
by cobalt irradiation at doses ranging from 2-10 Gy. Cells’ growth was measured by 3Hthymidine uptake test.
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pGLl-TNF were injected intratumorally with a total volume of 225 pi. Equal amount of
PBS was injected into the control group. 18 hr, 48 hr and 168 hr (7 days) later, animals
were sacrificed. Supernatants of the processed tumor were subjected to analysis along
with the plasma by a high-sensitivity ELISA method. The results, as shown in Figure 8,
demonstrated that there was no TNF expression in tumors injected with PBS.
Statistically significant levels of TNF expressions were detected in all three groups
injected with pGLl-TNF at 18 hr and 48 hr. At 168 hr, in two groups of tumor bearing
mice injected with 150|iig and 450pg of pGLl-TNF, the amount of TNF detected was still
statistically significant. The expression level was the highest at 18 hr after injection, then
declined in the next two measurements. At 18 hr after injection, average TNF-a
expression levels were 403.5 pg (44.4 units)/ g of tumor, 713.5 pg (78.5 units)/g of tumor
and 765.1 pg (84.2 units)/g of tumor in the three pGLl-TNF-a injected groups (15, 150
and 450 pg respectively. No significant amount of TNF detected in plasma.
b. Effect of by expressed TNF-a on blood cell populations
At three measurement time points, the animals were euthanized and blood was
drawn. The blood samples were subjected to counts including RBC, WBC, hemoglobin.
hematocrit and platelets. Flow cytometric analysis was performed to determine WBC
differentiation and various populations of lymphocytes including T cell and subsets, B
cell and NK cells. Information of RBC, hemoglobin, hematocrit and platelets were listed
in Table 2. At day 7 after plasmid injection, RBC count in all tumor bearing groups
decreased significantly compared to no tumor control group. At the same time
hemoglobin and hematocrit in most of tumor bearing groups also decreased significantly
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Figure 8. Phase I in vivo study: TNF-a expression by intratumorally injected pGLlTNF in C6 tumor bearing athymic mice. 5 x lO5 C6 cells were injected
subcutaneously to athymic mice and allowed to establish for 7 days. Then PBS, 15 jag,
150 jag and 450 pg of pGLl-TNF were given intratumorally with total volume of 225 jal
to animals in appropriate groups. Animals were euthanized at 18, 72 (3 day) and 168 hrs
(7 day) after injection and supernatants of processed tumor were subjected to analysis for
TNF-a expression by a standard ELISA method. Unit of expression shown as pg of
TNF-a/ g of tumor.
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Table 2. Phase I in vivo study hematological evaluation

Group

RBC
(x 106/ml)

Hemoglobin
(g/dl)

No tumor

7.61 +/- 0.34Tf

13.3 +/-0.5

(%)
40.1 +/- 1.7

Tumor-bearing
PBS
pGLl-TNF(15 pg)
pGLl-TNF(150 pg)
pGLl-TNF(450 pg)

7.60 +/- 0.56
6.99+/- 0.14
7.33 +/- 0.18
7.16+/-0.09

13.7+/- 0.9
12.8 +/- 0.3
13.1 +/- 0.3
13.2+/-0.2

41.6+/-2.8
38.3 +/- 0.9
39.3 +/- 0.9
39.1 +/- 0.4

450+/-114
368 +/- 79
391 +/- 77
193 +/- 33

3 days

PBS
pGLl-TNF(15 pg)
pGLl-TNF(150 pg)
pGLl-TNF(450 pg)

6.94+/- 0.12
6.01 +/- 0.62
6.85 +/-0.15
6.23 +/- 0.68

12.6 +/- 0.2
11.2 +/- 1.1
12.5 +/-0.3
11.5 +/- 1.2

37.8 +/- 0.5
32.8 +/- 3.4
36.8 +/- 0.8
33.9+/-3.7

620+/- 23
603 +/-104
465 +/- 43
237+/- 54e

7 days

PBS
pGLl-TNF(15 pg)
pGLl-TNF(150 pg)
pGLl-TNF(450 pg)

6.05
5.53
6.33
4.89

11.2 +/-0.6
10.5 +/- 0.5c
11.8+/-0.2
9.4 +/. o.7c d

32.2
30.9
34.4
26.9

226+/302+/328 +/379+/.

Time3

18 hr

+/- 0.36c
+/- 0.3lc
+/-0.11c
+/-0.40c,d

aTime after treatment.
Mean +/- SEM; n = 5-7 mice/group.
cp<0.05 vs no tumor.
dp<0.05 vs pGLl-TNF (150 pg) at 7 days.
ep<0.05 vs PBS and pGLl-TNF (15 pg) at 3 days.
i_
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Hematocrit

+/- 1.9C
+/- 1.5C
+/- 0.6
+/- 2.0c,d

Platelets
(x 103/ml)
383 +/- 67

59
29
64
34

compared to no tumor control group. There was almost no significant difference in
platelets counts between all groups in all three measurements.
Figure 9 showed a sample sheet of the data acquired by flow cytometry and the
differentiation of B and NK cells from samples were illustrated as the panel in Figure 10.
B and NK cell populations can be easily discerned and thus gated seperately for later
analysis.
Shown in Table 3 was WBC counts and percentages of lymphocyte and
monocyte/granulocyte. There was no significant difference on WBC counts between all
tested groups in all three times. At all three time points that measurements were taken,
all tumor bearing animals demonstrated significantly decreased lymphocyte percentages
and significantly increased monocyte/granulocyte percentges.
Table 4 and Table 5 listed percentages and counts of T cells and their subsets in
the blood lymphocyte population. There were sporadic significant differences between
various groups as shown in the tables. Overall, there was no consistent change in these
lymphocytes either related to the tumor presence or plasmid injection. However, shown
in Figure 11 andl2, at 18 hr after plasmid injection, percentages of B cells in tumor
bearing animals injected with 450 pg pGLl-TNF decreased significantly compared to all
other tumor bearing animals while percentages of NK cells of same group increased
significantly compared to all other groups. Figure 13 demonstrated that at 18 hr after
plasmid DNA injection, while TNF-oc was at the highest level, spontaneous blastogenesis
value from group received pGLl-TNF-oc injection was significantly increased. The value
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Figure 9. Data sheet sample generated by flow cytometry.
Blood was drawn at
time of animal euthanasia with syringes containing heparin (100 units/ml). Cells were
labelled using a panel of mAh conjugated to FITC or PE then subjected to flow
cytometry analysis. Emission of fluorescence were collected and analyzed by computer.
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Figure 10. B and NK cell determination by flow cytometry.
Blood cells were
labelled using a panel of mAb conjugated to FITC or PE then subjected to flow
cytometry analysis. B and NK cell were labelled by B220 and Pan-NK respectively.
Panel of data sheets represents B and NK cell samples analyzed from each group at
different time points as marked.
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Table 3. Phase I in vivo study white blood cell counts (WBC) and percentages of
lymphocytes, monocytes and granulocytes in blood

Time3

18 hr

3 days

7 days

Group
No tumor

WBC
(x 106/ml)
6.97 +/- 0.96c

percentage15
lymphocytes
Mono/granule
71.5+/-2.95
28.00 +/- 2.83

Tumor-bearing
PBS
pGLl-TNF(15 pg)
pGLl-TNF(150 pg)
pGLl-TNF(450 pg)

4.16+/6.09 +/5.91 +/5.84 +/-

0.56
0.68
0.71
0.49

53.40+/- 1.44e
53.14+/- 1.90e
52.86 +/- 0.83e
47.43 +/- 1.81e

46.20 +/46.43 +/46.57 +/52.29+/-

PBS
pGLl-TNF(15 pg)
pGLl-TNF(150 pg)
pGLl-TNF(450 pg)

5.88 +/- 0.37
5.26 +/- 0.17
7.71 +/- 0.90

54.40+/-3.25f
55.33 +/- 2.46f
61.83 +/- 1.83
58.33 +/- 1.09f

44.80 +/- 3.20e
43.83 +/- 2.43'
37.67+/- 1.86s
41.00+/- 1.24f

PBS
pGLl-TNF(15 pg)
pGLl-TNF(150 pg)
pGLl-TNF(450 pg)

8.62
6.97
8.21
8.08

56.60 +/55.50+/54.14+/61.83 +/-

40.00 +/- 1.79e
44.33 +/- 1.91e
45.14+/-2.11g
37.50+/-2.1 lg

7.70 +/- 0.27d

+/+/+/+/-

0.69
0.67
0.66
1.01

1.75g
1.96e
1.99e
1.01g

1.50e
1.70e
0.92e
1.89e

aTime after treatment.
Percentages were obtained by flow cytometry analysis using forward and side light
scatter.
cMean +/- SEM; n = 5-7 mice/group.
dp<0.05 vs pGLl-TNF ( 150 pg) at 3 days.
ep<0.001 vs No tumor.
‘pO.Ol vs No tumor. [p=0.053, pGLl-TNF (150 pg) vs No tumor on day 3.]
g
p<0.05 vs No tumor.

b
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Table 4. Phase I in vivo Study percentages of T cells and their subsets in the blood
lymphocyte population

T cells(CD3+)
0.198+/-0.035

Percentage”
Th cells(CD4+)
0.117+/-0.031

Tc cells(CD8+)
0.057+/-0.011

Tumor-bearing
PBS
pGLl-TNF(15 pg)
pGLl-TNF(150 pg)
pGLl-TNF(450 pg)

0.216+/-0.017
0.286+/-0.057
0.194+/-0.031
0.180+/-0.024

0.198+/-0.015
0.177+/-0.020
0.156+/-0.032
0.067+/-0.010g

0.102+/-0.010
0.099+/-0.007
0.090+/-0.014
0.067+/-0.007

3 days

PBS
pGLl-TNF(15 pg)
pGLl-TNF(150 pg)
pGLl-TNF(450 pg)

0.160+/-0.013
0.158+/-0.020
0.105+/-0.014d
0.217+/-0.022

0.110+/-0.016
0.090+/-0.010
0.070+/-0.009
0.107+/-0.027

0.086+/-0.012
0.080+/-0.015
0.058+/-0.013
0.077+/-0.012

7 days

PBS
pGLl-TNF(15 pg)
pGLl-TNF(150 pg)
pGLl-TNF(450 pg)

0.214+/-0.041
0.103+/-0.022 e,f
0.090+/-0.011 e,f
0.063+/-0.013 e,f

0.110+/-0.018
0.062+/-0.011
0.064+/-0.006
0.033+/-0.006h

0.098+/-0.031
0.068+/-0.011
0.077+/-0.011
0.033+/-0.005

Time3

18 hr

Group
No tumor

aTime after treatment.
Percentages were obtained by flow cytometry analysis using fluorescence-labelled
monoclonal antibodies.
cMean +/- SEM; n = 5-7 mice/group.
dp=0.05 vs no tumor and pGLl-TNF (450 pg) at 3 days.
ep<0.05 vs no tumor.
fp<0.05 vs PBS at 7 days.
gp<0.05 vs PBS and pGLl-TNF (15 pg) at 18 hr.
hp<0.05 vs no tumor and PBS at 7 days.
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Table 5. Phase I in vivo study numbers of T cells and their subsets in the blood

Time3

18 hr

Group
No tumor

Number of cells (x 10 /ml)b
T cells(CD3+)
Th cells(CD4+)
Tc cells(CD8+)
9.97 +/- 2.00c
5.57+/- 1.54
2.81 +/- 0.82

Tumor-bearing
PBS
pGLl-TNF(15 pg)
pGLl-TNF(150 pg)
pGLl-TNF(450 pg)

4.74 +/- 0.65
9.28+/-2.16
6.28+/- 1.34
4.68 +/- 0.33

4.30 +/5.72 +/5.26+/1.82+/-

3.45 +/- 0.45
2.58 +/- 0.29
3.34+/- 0.46
5.41 +/- 2.22

2.81 +/- 0.82
2.63 +/- 0.07
2.24 +/- 0.38
2.77 +/- 0.63

5.68 +/- 0.95
2.37 +/- 0.46
2.85+/- 0.31
1.75 +/- 0.45f

5.22 +/2.50 +/3.35 +/1.85 +/-

3 days

PBS
pGLl-TNF(15 pg)
pGLl-TNF(150 pg)
pGLl-TNF(450 pg)

5.65
4.65
5.01
9.43

7 days

PBS
pGLl-TNF(15 pg)
pGLl-TNF(150 pg)
pGLl-TNF(450 pg)

9.08 +/- 0.25
4.26 +/- 0.13
3.84+/- 0.31e
3.43 +/- 1.04e

+/- 0.91
+/- 0.71d
+/- 0.74d
+/- 0.96

0.59
0.90
1.41
0.29

2.22 +/3.16+/3.00+/1.81 +/-

0.32
0.44
0.82
0.23

1.84
0.37
0.45
0.50

aTime after treatment.
Percentages were obtained by flow cytometry analysis using fluorescence-labelled
monoclonal antibodies.
LMean +/- SEM; n = 5-7 mice/group.
dp=0.05 vs no tumor. e(p=0.052 and 0.062 vs no tumor). ^<0.05 vs no tumor and PBS.

b
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Figure 11. Effect of pGLl-TNF on blood B cell percentage in C6 tumor-bearing
athymic mice. B cell population was determined by labeling cells with mAb against
the B220 marker using flow cytometry. Each column represents the mean +/- S.E.M..
Significantly lower than all other groups.
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□ pGL1-TNF (150ug)
■ pGL1-TNF (450ug)
day 7

Figure 12. Effect of pGLl-TNF on blood NK cell percentage in C6 tumor-bearing
athymic mice. NK cell population was determined by labeling cells with mAb against
the Pan-NK marker using flow cytometry. Each column represents the mean +/Significantly higher than all other groups (p<0.05).
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□ No tumor
□ Tumor control (PBS)
0pGL1-TNF (15ug)
□ pGL1-TNF (150ug)
■ pGL1-TNF (450ug)
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Figure 13. Phase I in vivo study: Spontaneous blastogenesis of peripheral blood.
Each column represents the mean +/- S.E.M. The dotted line represents the average
value of no tumor control group. Significantly higher than the rest of groups(p<0.05),
Significantly higher than normal control, PBS, and pGLl-TNF (15p.g) groups (p<0.05).
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were then decreased in the next two measurements. B cell and NK cell counts were listed
in Table 6.
2. Phase IIin vivo study: Effect ofpGLl-TNF-a, with and without transfection
reagent, on C6 tumors in combination with 60Co radiation
a. Effect of SuperFect™ on combination treatment of C6 tumors
To evaluate the effect of pGLl-TNF-a on C6 tumors’ progression in combination
with 60Co radiation and to test if the transfection reagent had facilitated pGLl-TNF-a’s
uptake in vitro will be able to facilitate the uptake in vivo, the following experiment was
performed. Subcutaneous C6 tumors were allowed to become established in athymic
mice before initiating treatment. PGLl-TNF-a, with and without the reagents
encasement, was injected intratumorally at a dose of 50 pg/injection (+/- 15 pg
SuperFect) 9 days after tumor cell implantation. Tumor irradiation with the 60Co source
(2 Gy/fraction), was administered to the appropriate groups 16-18 hr later. Each
modality was delivered three times [ pGLl-TNF-a (+/- SuperFect) on days 9, 13, and 16;
radiation on days 10, 14, and 17]. Figure 14 showed that the combination of pGLl-TNFa with 60Co radiation was as effective in slowing tumor progression as pGLl-TNF-a
combined with 60Co radiation and the transfection reagent. The transfection reagent
encasement, thus, was not necessary in order for the pGLl-TNF-a achieve a radiation
enhancing effect against C6 tumors in vivo. Either radiation or pGLl-TNF-a (with or
without SuperFect™) as single modalities did not slow the growth of the established
tumors significantly under the conditions used. Significantly smaller tumor volumes
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Table 6. Phase I in vivo study B and NK cell counts in blood

Group
No tumor

Number of cells (x 10(7ml)
B cells (B220+)
NK cells (PanNK+)
4.21 +/- 0.70b
0.76+/- 0.11

Tumor-bearing
PBS
pGLl-TNF(15 pg)
pGLl-TNF(150 pg)
pGLl-TNF(450 pg)

1.65 +/- 0.27c
2.37 +/- 0.39c
2.18+/- 0.27c
1.62+/- 0.24c

0.58+/- 0.11
0.87 +/- 0.06
0.94 +/- 0.13
1.18+/- 0.15d

3 days

PBS
pGLl-TNF(15 pg)
pGLl-TNF(150 pg)
pGLl-TNF(450 pg)

2.53 +/- 0.41
2.28+/- 0.17C
3.84+/- 0.17
3.51 +/- 0.43

0.71 +/- 0.09
0.63 +/- 0.04
0.91 +/- 0.07
1.00 +/- 0.14

7 days

PBS
pGLl-TNF(15 pg)
pGLl-TNF(150 pg)
pGLl-TNF(450 pg)

3.94 +/- 0.40
3.01 +/- 0.38
3.45 +/- 0.37
3.95 +/- 0.72

1.18+/- 0.19
0.90+/- 0.11
1.05+/- 0.10
1.08 +/- 0.09

Time3

18 hr

aTime after treatment.
bMean +/- SEM; n = 5-7 mice/group.
cp<0.05 vs no tumor.
dp<0.05 vs PBS at 18 hr.
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Figure 14. Phase II in vivo study: a. Effect of SuperFect™ on combination
treatment on C6 tumors.
The appropriate groups received intratumoral injections of
plasmid DNA at 50 pg/injection with/without the polyamine transfection reagent,
followed 16-18 hr later by a 2 Gy dose of cobalt irradiation on tumor bearing leg. Each
treatment regimen was given three time totally.
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were found in the group receiving combination treatment compared to the other groups
(p<0.05).

b. Effect of pGLl-TNF-a, without transfection reagent, on C6 tumors in
combination with 60Co radiation
After it was determined that SuperFect™ did not improve the effect of plasmid
DNA and radiation combination treatment, the experiment was repeated, and analyses
were done including WBC counts, relative spleen weight, the spontaneous blastogenesis
of blood cells and the spleen cells’ response to LPS stimulation were analyzed. Tumor
progression of all tested groups was shown in Figure 15. In the last three measurements
at day 12,14 and 16 that were taken, the combination treatment group was the only group
showed significantly slowed tumor progression compared to nontreated tumor group.
WBC counts and relative spleen weights were summarized in Table 7. Nontreated tumor
and 60Co radiated tumor groups showed significant increase of relative spleen weight
compared to no tumor animal group. There was no significant difference in WBC counts
between all tested groups. In Figure 16, it demonstrated that spontaneous blastogenesis of
the combination treatment group was significantly higher that all other tested groups.
Figure 17 showed that there was no significant difference of splenocyte stimulation index
between all tested groups.
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Figure 15. Phase II in vivo study: b. Effect of pGLl-TNF-ct, without transfection
reagent, on C6 tumors in combination with 60Co radiation.
Treatments initiated 7
days after C6 tumor cell implantation. The appropriate groups received intratumoral
injections of plasmid DNA at 50 pg/injection, followed 16-18 hr later by a 2 Gy dose of
cobalt irradiation on tumor bearing leg. Each regimen were repeated three times.
Significantly smaller than nontreated tumor, 60Co and pWS4 + 60Co groups (p<0.05).
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Table 7. Phase II in vivo study white blood cell counts and Relative spleen weights
Group

WBC counts3
(x 106/ml)

Relative spleen weight5
(x 10"3)

No tumor

6.25 +/- 1.23c

4.91 +/- 0.89

Nontreated tumor

7.01 +/- 1.00

7.43 +/- 0.42d

60Co

5.56 +/- 0.73

7.62 +/- 0.44d

pWS4 + 60Co

4.25 +/- 0.80

6.35 +/- 0.37

pGLl-TNF + 60Co 4.06+/-0.31

6.53 +/- 0.35

aWhite blood cell counts obtained by the trypan blue exclusion method.
bRelative spleen weight obtained by weighing weights of animal body and spleen, then
calculated by formula RSW = weight of spleen / weight of animal body.
LMean +/- SEM; n = 4 mice/group.
dp<0.05 vs no tumor.
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Figure 16. Phase II in vivo study: Spontaneous blastogenesis of peripheral blood.
Each column represents the mean +/- S.E.M. Significantly higher than normal control,
nontreated tumor and 60Co (p<0.05), bSignificantly higher than normal control (p<0.05).
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Figure 17. Phase II in vivo study: stimulation index of splenocytes upon LPS
stimulation. Each column represents the mean +/- S.E.M. There was no significant
difference between all groups.
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3. Phase III in vivo study:

Effect ofpGLl-TNF-a in different doses on C6 tumors in

combination with 60Co radiation
In this study, different doses of pGLl-TNF-a were injected intratumorally in
combination with 60Co irradiation of the tumor, it was expected that different amounts of
the plasmid would show differences in enhancing 60Co radiation’s tumor inhibition effect.
The three different doses of pGLl-TNF-a are 15 pg, 150 pg and 450 pg respectively.
The treatments were initiated on day 9 when palpable tumor masses were observed. At
day 18, all animals were euthanized, blood and spleen samples were subjected to
different analyses. Figure 18 showed that pGLl-TNF-a at doses of 15pg andl50pg, in
combination with 60Co radiation significantly slowed the C6 tumor progression compared
nontreated tumor group while other control groups did not. The last three measurements
were all significantly different. There was no significant difference between these two
combination groups. PGLl-TNF-a at dose of 450pg, combined with 60Co radiation, did
not significantly slow the tumor growth compared to the nontreated tumor groups.
Various tests were performed at the time of euthanasia including WBC counts,
relative spleen weight, whole blood spontaneous blastogenesis and spleen cell LPS
stimulation. T cells and their subsets, B cells and NK cells in both blood and spleen were
analyzed by using flow cytometry. WBC counts and relative spleen weight, blood cell
spontaneous blastogenesis and Stimulation index of spleen cells were summarized in
Table 8 and 9. Percentages and counts of T cells and their subpopulations in blood and
spleen, percentages and counts of B and NK cells in blood and spleen from all tested
groups were listed in appendix 1. In most tumor bearing groups except nontreated tumor
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Figure 18. Phase III in vivo study: C6 tumor progression in athymic mice treated
with different doses of pGLl-TNF-a and cobalt radiation.
Treatments initiated 9
days after C6 tumor cell implantation. The appropriate groups received intratumoral
injections of plasmid DNA at 5, 50 and 150pg/injection, followed 16-18 hr later by a 2
Gy dose of cobalt irradiation on tumor bearing leg. Each regimen was repeated three
times. abPGLl-TNF (15 ng) + 60Co and pGLl-TNF (150 pg) + 60Co vs pGLl-TNF
(150 pg) and nontreated control (p<0.05).
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Table 8. Phase III in vivo study White blood cell counts and Relative spleen weights
Group

(x 10‘3)

No tumor

WBC countsa
(x 106/ml)
6.88 +/-1.08c

Nontreated tumor

6.78 +/- 0.81

5.42+/- 0.35

pGLl-TNF (150pg)

7.90+/- 1.20

7.12+/- 1.01

60Co

4.72 +/-0.23

4.89 +/- 0.19

pWS4 (150pg)/60Co

4.52 +/- 0.23

6.09 +/- 0.31

pGLl-TNF (15pg)/60Co

3.82 +/- 0.23d

5.54 +/- 0.73

pGLl-TNF (150pg)/60Co

4.54 +/- 0.25

5.53 +/- 0.35

pGLl-TNF (450pg)/60Co

4.68 +/- 0.56

6.60 +/- 0.26

Relative spleen weight0
4.81 +/-0.50

aWhite blood cell counts obtained by the trypan blue exclusion method.
bRelative spleen weight obtained by weighing weights of animal body and spleen, then
calculated by formula RSW = weight of spleen / weight of animal body.
cMean +/- SEM; n = 4 mice/group.
dp<0.05 vs pGLl-TNF (15pg).
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Table 9. Phase III in vivo study Whole blood spontaneous blastogenesis and spleen
cell stimulation index
Group
No tumor

Spontaneous Blastogenesisa Stimulation Indexa
(dpm/106 cell)
577.4 -/- 35.lh
196.8 +/- 39.8C

Nontreated tumor

386.1 +/- 39.8

138.4 +/- 28.lc

pGLl-TNF (150pg)

484.2 +/- 153.4

103.8+/- 18.9

60Co

837.9+/- 137.5

71.2+/-21.1

pWS4(150ng)/60Co

555.9 +/- 66.8

81.7+/- 16.5

pGLl-TNF (15pg)/60Co

1073.6+/- 190.5

99.1 +/-21.9

pGLl-TNF (150pg)/60Co

712.1 +/- 156.9

135.1 +/- 25.4

pGLl-TNF (450pg)/60Co

834.9 +/- 123.9

93.4+/- 23.5

'Spontaneous blastogenesis and Stimulation index were obtained using H-Thymidine
uptake methods stated in Material and Method chapter.
bMean +/- SEM; n = 5-6 mice/group.
cp<0.05 vs pGLl-TNF/60Co (15pg).
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group, the percentage of NK cells in spleen decreased significantly compared to no tumor
group.
Tumor histopathology
Figure 19 showed a panel of H & E stained C6 tumor sections demonstrating
changes of the tumor histopathology. It demonstrated tumor morphological differences
between tested groups, as panel A and B were taken from nontreated tumor and tumor
received either one of the treatments. Panel C and D was taken from tumors that received
combination treatments.
Sections of representative tumors from each group in the phase III in vivo study
were reviewed together with a pathologist. The sections were coded so that the review
was performed without prior knowledge of treatments. Results indicated that in
nontreated tumors and tumors given either pGLl-TNF-a or 60Co alone had large areas of
necrosis and significant areas of hemorrhaging (Panel C of Figure 19). There were very
few neutrophils present within the whole tumor sections that were scanned, and moderate
vasculature distribution (Panel A and B). The morphology of the necrotic areas
suggested that most of necrosis was in the early stage, (i. e., it occurred shortly before
mouse euthanasia). An example of the hemorrhage and early stage of necrosis was shown
in Figure 20. Within the tumor from the groups receiving pWS4/60Co or pGLl-TNF-a
(at all three doses)/60Co, the necrotic areas were smaller, but also exhibited concurrent
areas of hemorrhage. These latter two groups also had significantly more
polymorphonuclear (PMN) cell infiltration within tumor adjacent to the necrotic areas as
shown in Figure 21. And vasculature distribution was moderate. The morphological
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Figure 19. Hematoxylin and Eosin staining of C6 tumor xenograft in athymic mice.
C6 tumors were excised from animal at time of euthanasia, fixed in 10% formalin,
sectioned at 5 (am thickness, stained with H & E and subjected to microscopic
examination (Magnification 200 x). A and B, well growing regions of nontreated C6
tumor. Black arrow points to small blood vessel within tumor, white arrow points to
muscle fiber surrounded by invading C6 tumor cells. C and D, necrotic regions within
C6 tumors treated with pGLl-TNF and cobalt radiation. C, black arrow points to
hemorrhage within necrotic region; D, black arrow points to polymorphonuclear
neutrophils, white arrow points to late necrotic region with no visible cellular structure.
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Figure 20. Hemorrhage and early stage necrosis in C6 tumor C6 tumors were
excised from animal at time of euthanasia, fixed in 10% formalin, sectioned at 5 jam
thickness, stained with H & E and subjected to microscopic examination (Magnification
200 x). White arrows pointed to hemorrhages within the C6 tumor. Black arrow pointed
to early necrotic regions within the tumor.
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Figure 21. Different stages of necrosis and neutrophil infiltration in C6 tumor
C6
tumors were excised from animal at time of euthanasia, fixed in 10% formalin, sectioned
at 5 pm thickness, stained with H & E and subjected to microscopic examination
(Magnification 200 x). Black arrows pointed to different stages of tumor necrosis (from
right to left: early-middle-late stages of necrosis). White arrows pointed to infiltrated
neutrophils within early necrotic region of the tumor.
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features of the necrosis suggested a later stage than that observed in the tumors receiving
only pGLl-TNF-a or 60Co as single modalities (Figure 20). In tumor sections from the
pGLl-TNF-ct (450pg)/60Co group, few scattered apoptotic cells were found within the
“normal” growing tumor region (section not shown here). The overall impression was
that, although the necrosis seen correlated with the size of tumor (the larger the tumor,
the larger the necrosis region), there was more neutrophil infiltration within tumors
treated with the DNA/radiation combination. Also, it appeared to be quite likely that the
necrosis had been resulted earlier due to the DNA/radiation treatment. Mononuclear cells
including lymphocytes, monocytes and NK cells were not evaluated due to limitations of
the staining.
4. Phase IVin vivo study:

Effect ofpGLl-TNF-aon C6 tumors in combination with

proton radiation
With the successful synergistic C6 tumor inhibition effect of pGLl-TNF-a and
60

Co radiation observed, further evaluation tests were performed to explore the

combination effect of pGLl-TNF-a and proton radiation. In this study the schedule of
treatment regimens were changed. This was based upon the previous results obtained in
our laboratory on three different tumor models. C6 tumor cells were injected
subcutaneously into the right thigh of each mouse. Treatments started three days after the
injection. PGLl-TNF-a was injected into the same area of the tumor injection site, at the
dose of 50 pg/injection. Tumor bearing legs of the animals were irradiated 16-18 hours
later by the proton source. Since the treatments were initiated earlier, there was enough
time for each modality to be delivered four times to the designated groups. All mice

97

were euthanized when nontreated control tumors reached 2000mm3. The tumor
progression curves were shown in Figure 22. Tumor volumes of the groups treated with
proton radiation only or combined with proton radiation were significantly smaller than
all other groups without proton radiation in the last two measurements. However, there
was no significant difference on tumor volumes between group of only proton treatment
and the group of pGLl-TNF-a and proton combination. The synergistic inhibition effect
we observed in phase I study with pGLl-TNF-ct and 60Co radiation was not shown here.
5. Phase V in vivo study:

Comparison of60Co and proton radiation effects on C6

tumors in combination with pGLl-TNF-a
To clarify if the failure of showing synergistic tumor inhibition effect in phase III
were due to the change of treatment schedule or the treatment regimen itself, the
following study was performed. C6 tumor cells were injected subcutaneously as stated in
previous studies. In this study the treatment did not start until day 7 when palpable tumor
masses were observed. A pGLl-TNF-a and 60Co combination group to serve as control
and also in attempt to compare with the pGLl-TNF-a and proton combination group.
PGLl-TNF-a was given intratumorally at a dose of 50mg each injection, followed by
irradiation 16-18 hr later. Each treatment regimen was given three times till tumor
volume of control group reached 2000mm3. All animals were euthanized at day 16,
blood and spleen samples were subjected to further analyses. Figure 23 showed C6
tumor progressions of each group in the study. The pGLl-TNF-a and proton radiation
combination group had the smallest average tumor volumes compared to nontreated
tumor group in the last three measurements. Same result was observed from the group
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Figure 22. Phase IV in vivo study: C6 tumor progression in athymic mice treated
with pGLl-TNF-a and proton radiation. Treatments initiated 3 days after C6 tumor
cell implantation. The appropriate groups received intratumoral injections of plasmid
DNA at 50 pg/injection, followed 16-18 hr later by a 2 Gy dose of cobalt irradiation on
tumor bearing leg. Each regimen was repeated three times.
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Figure 23. Phase V in vivo study: C6 tumor progression in athymic mice treated
with pGLl-TNF-a and cobalt or proton radiation. Treatments initiated 7 days after
C6 tumor cell implantation. The appropriate groups received intratumoral injections of
plasmid DNA at 50 pg/injection, followed 16-18 hr later by a 2 Gy dose of cobalt or
proton irradiation on tumor bearing leg. Each regimen was repeated three times. aPGLlTNF + proton vs pGLl-TNF, 60Co and nontreated tumor (p<0.05), pGLl-TNF + 60Co vs
pGLl-TNF (p<0.05), bPGLl-TNF + proton vs pGLl-TNF and nontreated tumor
(p<0.05).
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received pGLl-TNF-a and 60Co radiation combination treatment. There was no
significant difference between the pGLl-TNF-a proton combination group and pGLlTNF-a 60Co combination group, as well as between proton control group and 60Co
control group.
Various tests were performed at the time of euthanasia including WBC counts,
relative spleen weight, whole blood spontaneous blastogenesis and spleen cell LPS
stimulation. T cells and their subsets, B cells and NK cells in both blood and spleen were
analyzed by using flow cytometry. WBC counts and relative spleen weight, blood cell
spontaneous blastogenesis and stimulation index of spleen cells were summarized in
Table 10 and 11. Percentages and counts of T cells and their subpopulations in blood and
spleen, percentages and counts of B and NK cells in blood and spleen from all tested
groups were listed in appendix 2. In all tumor bearing groups including the two
combination treatment groups, the percentages and counts of NK cell in spleen were
significantly lower than no tumor group. In B cell percentages, the two combination
treatment groups are significantly higher than no tumor groups.
6. Safety ofDNA injection and radiation
In all treatment groups involving injection of plasmid DNA, there was no weight
loss, swelling, inflammation, reduced activity or any other signs of side effect among the
tested animals. Unexpected complications are always possible when combining
therapeutic modalities like TNF and radiation that by themselves can produce serious side
effects. However, in this study all animals remained active and exhibited no overt signs
of toxicity.
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Table 10. Phase V in vivo study White blood cell counts and relative spleen weight
Group
No tumor

WBC counts3
(x 106/ml)
5.30+/-0.19cde

Relative Spleen Weight0
(x 10‘3)
5.40 +/- 0.25

Nontreated tumor

8.90 +/- 0.53

5.30+/- 1.23

60Co

5.30+/- 1.03de

5.33 +/- 0.24

Proton

6.50 +/- 0.54

5.70 +/- 0.16

pGLl-TNF (150|ug)

9.00+/- 0.71

6.48 +/- 0.11

pGLl-TNF (150pg)/60Co

6.40 +/- 0.55

6.20 +/- 0.22

pGLl-TNF (150pg)/proton

7.30 +/- 0.98

6.53 +/- 0.57

aWhite blood cell counts obtained by the trypan blue exclusion method.
bRelative spleen weight obtained by weighing weights of animal body and spleen, then
calculated by formula RSW = weight of spleen / weight of animal body.
cMean +/- SEM; n = 4 mice/group.
dp<0.05 vs nontreated tumor.
ep<0.05 vs pGLl-TNF.
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Table 11. Phase V in vivo study Whole blood spontaneous blastogenesis and spleen
cell stimulation index
Group
No tumor

Spontaneous Blastogenesis2 Stimulation Index3
( dpm/106 cell)
499.3 +/- 76.9b
567.7 +/- 77.9

Nontreated tumor

471.2+/- 107.3

456.7 +/- 86.3

60Co

527.3 +/- 197.0

307.1 +/- 26.3

Proton

517.6+/-50.1

324.2 +/- 81.7

pGLl-TNF (150pg)

410.8+/- 52.9

327.0+/- 78.1

pGLl-TNF (150pg)/60Co

450.3 +/- 58.1

333.3 +/- 61.1

pGLl-TNF (150pg)/proton

631.7 +/- 178.2

286.1 +/-61.6

Spontaneous blastogenesis and Stimulation index were obtained using 3H-Thymidine
uptake methods stated in Material and Method chapter.
bMean +/- SEM; n = 5-7 mice/group.
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CHAPTER FOUR
DISCUSSION

A. Brief overview
TNF-a exhibits both direct and indirect anti-tumor effects. Although a certain
degree of success has been reported using localized delivery of the protein, most clinical
trials that have employed the agent alone at high systemic doses have been disappointing
(Tada et ah, 1993 and Yamasaki et al, 1994). Dose -limiting toxicities that have been
observed during high dose TNF-a treatment include hypotension (resembling the
vascular leak syndrome seen with interleukin 2), fever/chills, renal impairment, and
leukopenia. However, the agent has proven to be beneficial when used in conjunction
with certain chemotherapeutic drugs such as melphalan (Eggermont et al., 1996 a;
Eggermont et al., 1996 b; and Manusama et al., 1996). The ability of TNF-a to induce
oxygen radical production by tumor cells, as well as by neutrophils and macrophages that
may be infiltrating a tumor (Rubin et al., 1988 and Zimmerman, et al., 1989), and its
ability to induce tumor cell apoptosis (Tartaglia et al., 1993) have been associated with
the enhancing effect of TNF-a on other treatment modalities. In addition, Seung et al.
(1995) and Mauceri et al. (1996) have achieved positive results by delivering TNF-a
intratumorally with viral vectors and liposome-mediated methods. These reports have
not only rejuvenated interest in TNF-a as a cancer therapeutic agent, but have also
widened the range of possibilities for its efficient and continuous delivery.

106

The overall aim in this research project was to explore the potential of TNF-a and
ionizing radiation as a combination treatment, as well as to search for efficient delivery
systems for the cytokine. So far, research done in Dr. Gridley’s laboratory has
successfully demonstrated that non-toxic doses of IV-administered TNF-a protein can
enhance radiation antitumor effects not only against relatively radiosensitive tumor types
(Gridley et al. 1994 and 1997 a), but also against a radioresistent and rather aggressive
glioma (C6) tumor (Gridley et al., 1997 b). Considering that advantages of plasmid DNA
delivery include low toxicity and low immunogenicity compared to virus or liposomemediated delivery methods, we employed plasmid DNA injection in the study. A major
goal, thus, was to first test and verify the concept that intratumoral plasmid-mediated
TNF-a gene delivery was a viable alternative approach that could be developed for use
together with radiation therapy.
Eukaryotic expression vector pWS4 is one of a series of vectors first developed
by Sheay et al. (1993). It contains a CMV promoter, a polyadenylation sequence, and the
tripartate leader sequence of adenovius (Avtl) located downstream of the promoter. It has
been demonstrated that the presence of Avtl fragment can increase gene expression
efficiency up to 18-fold, presumably because mRNA with this regulatory sequence binds
translation initiation factors with greater affinity than do cellular mRNAs (Merrick et al.,
1992). We ligated the TNF-a coding sequence into the polylinker site of pWS4. The
new plasmid construct was given the name pGLl-TNF-a.

107

B. In vitro expression of TNF-a on pGLl-TNF-a transfected C6 cells
In the in vitro studies, a cationic polyamine transfection agent SuperFect TM was
complexed with pGLl-TNF-a to facilitate uptake of the plasmid by C6 cells. No
detectable TNF-a protein was found in supernatants of C6 cells to which pGLl-TNF-a
(without the transfection agent) had been added. C6 cells transfected with the pGLlTNF-a/polyamine complex produced increasing amounts of TNF-a protein for up to 7
days. When supernatants were collected from transfected C6 cells in culture and added
to the TNF-a-sensitive L929 cells, the viability of the cells was decreased. In contrast,
supernatant from C6 cells incubated with pGLl-TNF-a without the polyamine had no
effect on L929 cell growth. This demonstrated that the polyamine reagent was necessary
for transfection of the C6 cells in vitro and that the TNF-a protein that was subsequently
expressed by the transfected C6 cells was biologically functional. It is also noteworthy
that in our preliminary experiments the transfection agent alone appeared to have an
strong inhibitory effect on growth of the C6 cells.
C. In vivo expression of TNF-a protein in C6 tumor xenografts injected with pGLlTNF-a

“Naked” gene transfer offers several advantages (Levy et al., 1996; Davis et al..
1993). “Naked” DNA gene transfer strategies do not require dividing cells, have
virtually no size limitation, and should be less likely to create immunological problems,
since plasmid DNA can be purified to homogeneity and DNA itself is a poor antigen.
Gene expression has been demonstrated by many groups by using various reporter genes
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in many different type of tissues, as discussed in the introduction chapter. Studies have
shown that in mouse skeletal muscle, which is a very slowly dividing tissue, plasmid
DNA transfer is more efficient than that of adenovirus and retrovirus vectors(Davis et ah,
1993). However, gene expression by plasmid DNA transfer in rapidly dividing tissue,
especially in tumors, still remained to be explored in greater depth. In our phase I in vivo
study, we attempted to evaluate the gene expression by plasmid DNA in rapidly dividing
C6 glioma xenografts. At three time points, 18 hr, 3 and 7 days after plasmid DNA
injection, supernatant from homogenized tumors were taken to determine the level of
expression. At all three doses of DNA injected (15, 150 and 450 pg), significant levels of
TNF expression were detected. The expression was the highest at 18 hr after injection,
then declined in the next two measurements. This suggests that the expression reached a
peak rapidly after DNA introduction. Also dose dependence was clearly shown here in
that 150 and 450 pg of DNA injected led to higher levels of expression compared to 15
pg of DNA injected and also longer TNF presence within the tumor. At all three time
points of measurements taken, there was no significant amount of TNF detected in
plasma indicating the expression was an local event rather than systemic.
In recent years, numerous studies have been done to test the efficacy of plasmid
DNA delivered gene expression in various tissues and organs, with or without the
facilitation of liposome or cationic lipid. Results generated from these investigations
varied in a wide range. Denham et al. (1998) showed that intraperitoneal (IP) injection of
plasmid DNA with liposome achieved maximal transfection in each tissue measured at 12
hours post-administration with decreasing reporter Chloramphenicol acetyl transferase
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(CAT) activity over the ensuing 14 days. Schulte, et al. (1998) reported that following
direct injection of plasmid DNA into the muscle or melanoma of individual Xiphophorus,
expression of a reporter gene gradually increased to a maximum at 6 days after injection
in both tissues and the level was maintained for at least 10 days after injection. Tsan et al
(1995) demostrated that expression of the reporter CAT gene was noted as early as 1 day
after intake of plasmid DNA, with or without liposome, in lung and lasted for more than
21 days. Expression has been shown to remain high and stable for at least 9 months in
skeletal muscle (Mir et al., 1998). However, it is virtually impossible to compare levels
of expression among these studies because different tissues or organs were targeted and
different techniques were involved in each study. Obviously, the characteristics of the
vector plasmid, encasement by liposome and its composition, the tissue or organ targeted,
route of delivery and other techniques like the use of electroporation could greatly affect
the outcome of gene expression. Among these factors, the means of administration
(delivery route) would also have an effect on the biodistribution of the plasmid, and thus
also the level of the expressed protein. Systemic delivery, like intravenous injection (IV),
has been shown to be able to distribute plasmid to multiple organs including lung, liver,
heart, kidney and spleen (Mahato et al. 1998; Mahato et al. 1995 and Thierry et al, 1995).
In contrast, after intratumoral injection of plasmid DNA, both the DNA and gene
expressing cells were limited to the vicinity of the injection site (Nomura et al. 1997).
The results we obtained showed that at the time the highest level TNF was measured
within the tumor (18 hr), there was no significant amount of TNF in plasma, suggesting
that the expression was localized without reaching the circulation. So far, there is no
clear understanding of mechanisms by which plasmid DNA is uptaken by cells to
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produce expression and how it is terminated. From the fact that long-term expression is
mostly observed in low-dividing cells like muscle fiber, we propose that a dilution effect
due to high proliferation rate of C6 cells contributes to the decrease of expression level in
our study. Further experiment is still needed to prove this hypothesis.
D. TNF-a receptor quantitation by LSC

In order to explore the mechanisms of C6 cell unresponsiveness to TNF-a in
vitro, we performed immunofluorescent staining and laser scanning cytometry analysis to
determine the existence and distribution of both P55 and P75 TNF-a receptors on C6
cells. Compared to L929 cells (TNF-susceptible), the total TNF-a receptor density on C6
cells was low. In addition, L929 cells had approximately equal levels of both receptors,
whereas C6 cells had a substantially higher P55 receptor intensity than that seen for P75.
When the TNF-a receptors were first discovered and, it was believed that the two types
of receptors had discrete functions, as well as separate signal transduction pathways.
Acitivation of P55 receptors, was thought to be sufficient to induce apoptosis through the
death domain of the receptor; activation of P75 receptors was believed to be needed for
NF-kB activation, thus leading to cell survival (Tartaglia et al, 1993). Recent studies,
however, have shown that the two types of receptor are likely to work in a cooperative
fashion. Several groups of investigators (Natoli et al., 1997 and Shu et al, 1996) have
shown that signal mediator TNF-a receptor associated factor-2 (TRAF-2) is able to bind
to both receptors. Weiss et al. (1997) demonstrated that over-expression of the P75
receptor greatly enhanced P55 receptor-mediated cytotoxicity. With this new
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information and the results shown here, we propose that not only the low denensity of the
receptors, but also the disproportionate frequency of the two types, may account for the
lack of sensitivity to TNF-ot seen with the C6 cells. Further investigations would include:
to over-express the P75 receptors on the C6 surface and observe any change in the
reaction after TNF-a’s addition; to establish L929 cell line variants with diminished
membrane P75 or P55 receptor presence and monitor the change in sensitivity to TNF-a
and to measure activity changes on the downstream caspase cascade.
E. Effect of pGLl-TNF-a on transfected C6 cells in combination with 60Co
radiation in vitro
As shown in the results chapter, pGLl-TNF-a transfected C6 cells with the
facilitation of the polyamine reagent, did not significantly slow C6 cell proliferation in
culture compared to the polyamine reagent alone. Also, pGLl-TNF transfection of the
C6 cells did not sensitize the tumor cell to various doses of 60Co radiation used in the
experiment. These results did meet our expectation that genetically delivered TNF-a
would demonstrate the same result as the TNF-a protein that in combination with 60Co,
TNF can not inhibit the growth of C6 cells in cell culture. Gridley et al. (1997 b)
previously reported that C6 glioma cells are not sensitive to TNF-a protein at doses
ranging from 5 to 500 unit/ml and that the cytokine does not enhance tumor cell
susceptibility to radiation in vitro. In the same publication, it was also shown that IV
injection of low non-toxic doses of TNF-a before the administration of radiation slowed
C6 tumor growth significantly more than did radiation alone. It is not uncommon that
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due to the complexity of animal models, compared to cell cultures, that results from in
vitro and in vivo tests are different, especially with cytokines like TNF which have
multiple systemic functions in addition to direct cytotoxicity when applied in vivo.
Barnhart, et al. (1998) have also shown that in similar studies, that cell culture systems
cannot readily substitute for in vivo testing of new plasmid constructs. All these findings
suggest that further animal experiments were needed to fully evaluate the new plasmid
and radiation combination approach.
F. Effect of polyamine transfection agent on the combination treatment
We also compared the effects of the cationic polyamine agent encapped pGLlTNF-a in combination with 60Co to plasmid DNA without the transfection agent
combined with 60Co radiation on C6 tumor progression. Both combinations were able to
significantly inhibit the tumor progression compared to single treatment regimens.
However, the effects were virtually not different between the two combination groups.
One explanation is that this polyamine agent was not able to improve the efficacy of
DNA uptake in the C6 tumor cells as it demonstrated in the in vitro study, and the
combination effect shown was from the direct cytotoxicity of the reagent itself. The
mechanisms of in vivo DNA uptake without facilitation agent is not quite clear to date.
There are, however, some hypotheses in this regard. One possibility is that the direct
injection of DNA damages or impairs target cell membrane integrity, hence the cells may
be able to pick up the plasmid more readily. Cationic liposome-mediated DNA injection
has been successful in gene delivery and target gene expression in many investigations.
but it has not yet been shown that the DNA within the positively charged particles has

113

higher entry efficiency compared to the “naked” DNA injection method. The structure of
the component used for in vivo transfection is different from that used in vitro tests, due
to differences in the surrounding environment of the cell. Therefore, each type of
transfection reagent should be carefully tested for its DNA uptake efficiency. With all
these considerations, we chose to perform “naked” DNA injection for all further studies
because our data showed it to be efficient, simple, direct, and effective.
G. Effect of pGLl-TNF-a on C6 tumors in combination with 60Co radiation
In this phase I in vivo study, the schedule of intratumoral pGLl-TNF-a injection
and tumor irradiation was based on our previous observations, as well as those of others,
that pretreatment with TNF-a protein results in a significant enhancement of radiation
effects. Treatments were initiated for the first time after the tumor had been allowed to
become established for 9 days, i.e., a palpable mass was present. This ensured the
accuracy of plasmid injection into the tumor rather than surrounding tissues, although 9
days is a relatively long time period considering the aggressive nature of the C6 cells.
Nonetheless, combination therapy of pGLl-TNF-a and 60Co resulted in significantly
slower tumor progression compared to the other groups. Either pGLl-TNF-a (150 pg
total) or the relative low dosage of radiation alone (6 Gy total) did not affect tumor
growth.
H. Effect of pGLl-TNF-a in different doses on C6 tumors in combination with 60Co
radiation
In determining the optimum dose range that pGLl-TNF-a can be used in
combination with 60Co radiation, we proceeded to the phase II in vivo study. Treatments
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were started after 7 days of tumor establishment, again when the tumor mass was first
visible and palpable. The same treatment schedule was used as in phase I. The results
showed that a dose of 150pg, pGLl-TNF-a in combination with 60Co radiation (6 Gy
total) slowed C6 tumor progression significantly. These results confirmed the
observations in phase I study. At the dosage of 15pg, the pGLl-TNF-a and 60Co
radiation combination was also able to slow the tumor progression significantly. The
degrees of tumor growth suppression in these two groups were very similar. The data
clearly showed that the 15pg dose of the pGLl-TNF-a was just as effective as the 150pg
dose. However, when pGLl-TNF-a was given at the dosage of 450pg, the synergistic
tumor inhibition achieved with the two lower doses was not achieved. The combination
of pGLl-TNF-a at this dose with 60Co radiation inhibited tumor growth at the same level
as 60Co radiation alone did. Also observed was the fact that the tumors in mice treated
with TNF-ct alone grew as well as (in phase I), or faster than tumors in untreated animals
as shown in this study. This and our previous results suggest that TNF-a at an excessive
level can enhance the C6 tumor growth. At least the beneficial effect was no longer
evident.
As is the case with a number of cytokines, TNF-a under certain conditions has the
potential to act as a tumor promoter (Malik 1992). For example, it has been reported that
TNF-a can to enhance the growth of BALB/3T3 cells and to facilitate carcinogenesis
associated with the okadaic acid pathway (Fujiki et al, 1994). This has led us to speculate,
that at doses of 15pg and 150pg, pGLl-TNF-a was able to produce an amount of TNF-a
that is enough to synergistically inhibit C6 tumor progression when used together with
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60Co radiation. When given at the dose of 450|ag, the amount of TNF-a produced may
have exceeded the level that was needed to augment 60Co radiation’s tumor killing effect.
The excessive amount of TNF-a expressed may have acted as a tumor promoter in tumor
cells that were not severely damaged by the treatments. This, in turn, may have allowed
these cells to grow more aggressively, thus neutralizing the synergistic inhibition
achieved with low doses of pGLl-TNF-a with 60Co radiation.

I. Effect of treatment schedule on pGLl-TNF-a and proton radiation combination
treatment of C6 tumor
After the success achieved with the combination of pGLl-TNF-a and 60Co
radiation, we proceeded to investigate the possibility that the combination of pGLl-TNFa and proton radiation may achieve a similar, if not better, C6 tumor inhibitory effect.
Although the two forms of radiation have different characteristics, both 60Co gamma rays
and proton are ionizing. Many studies of proton radiation indicated that it has a relative
biological effectiveness (RBE) of 1.1, when 60Co is used as the reference radiation
(RBE=1.0) and has better localization and focal energy deposition. We also expected
that the pGLl-TNF-a and proton radiation combination may have a stronger tumor
inhibitory effect than the combination of pGLl-TNF-a with 60Co radiation.
The C6 tumor cells were injected SC and all treatments were initiated after three
days instead of allowing the tumor to become established to a palpable level. In some
studies it has been shown that the tumor inhibition effect from combination treatment is
especially evident if administered when the tumor load is very small (Gridley et al, 1997).
Based on these observations we assumed that by initiating the treatment earlier, we would
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achieve greater tumor inhibition. The earlier start also allowed us to give each treatment
regimen four times instead of three times as in the previous studies. However, by the
time of euthanasia and running parameter analysis, the pGLl-TNF-oc and proton radiation
combination treatment group did not exhibit a significantly stronger anti-tumor effect
compared to proton radiation alone. A similar result was observed in one of our previous
studies by Baher et al., that treatments initiated 3 days after C6 cell injection did not show
the synergistic effect discussed above. A possible explanation for this phenomenon is
that because of the earlier start of the plasmid injection while the tumor was not well
established, the plasmid uptake efficiency by the tumor cells was lower, thereby causing
less TNF-cc production. Also, the vascularization of the tumor in this very early stage
may have been relatively poor, hence the cytokine being produced may have been less
well distributed to all tumor regions, resulting in fewer tumor cells being exposed to
TNF-a. Hence, the systemic effect of produced TNF-a was missing. Tumor cells are
well known to have poor intercellular communication compared to normal cells. Thus,
by delaying the treatments until the tumor mass is better established, we should able to
circumvent the problem and achieve the tumor inhibition effect again. Indeed, in
subsequent studies, this assumption was proven to be correct and will be discussed
further in the next section.
J. Comparison of pGLl-TNF-ct’s effect on C6 tumors in combination with 60Co
radiation and proton radiation
Given the success of the pGLl-TNF-a and 60Co radiation to synergistically
inhibit the C6 tumor progression and the fact that both 60Co and proton radiation share

117

the common feature of ionizing radiation, we strongly believed that the combination of
pGLl-TNF-a producing the cytokine and protons could also achieve the same synergistic
tumor inhibition effect, if not greater. To re-evaluate the results we obtained from the
phase III animal study, we designed a similar study, but added a pGLl-TNF-a and 60Co
radiation combination group as a control, as well as a comparison group. We also
prolonged the length of time between C6 cell injection and initiation of treatment, again
to evaluate the impact of treatment schedule on the tumor inhibition effect.
When C6 tumors reached palpable levels at day 7, the treatment was initiated by
injection of pGLl-TNF-a plasmid intratumorally and was followed by proton or 60Co
radiation to the appropriate groups 16 to 18 hr later. Each treatment regimen was
repeated three times. As we expected, tumor volumes of animals receiving the pGLlTNF-a in combination with proton radiotherapy were the smallest, and were significantly
different compared to all other groups except the pGLl-TNF-a/60Co group. The
combined pGLl-TNF-a and 60Co radiation treated tumors were significantly smaller than
those treated with 60Co radiation alone and other groups that did not receive any form of
radiation. These results proved that proton radiation can be successfully combined with
pGLl-TNF-a gene therapy and produce a synergistic anti-tumor effect. These data also
confirmed that, as for the plasmid DNA intratumoral injection, the time of treatment
initiation was critical to the successful outcome. This study showed that a certain level of
tumor mass has to be present at the time of the first pGLl-TNF-cc injection. There are
two hypotheses in explaining this phenomenon. First, the tumor volume before it reaches
a palpable level, was too small. There is the possibility that the injected plasmid DNA
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was not deposited directly, or perhaps was deposited only partially into the tumor cell
implantation site. Rather, it may have diffused into the surrounding tissue. Thus, the
efficiency of plasmid DNA uptake by the tumor cells may have been very low, resulting
in a level of TNF-a protein that was below the minimum needed amount to achieve its
effect before the administration of radiation. We attempted to ensure that the injected
DNA would reach the tumor by marking the site of tumor cell implantation and by
measuring the syringe needle length. Technical error, however, still cannot be
completely ruled out. Secondly, there are several reports discussing the interaction
between TNF-a and the vasculature of tumor. Mauceri, et al. (1996) reported in a similar
study that the TNF-a expression, which was elicited by ionizing radiation, selectively
damaged SQ-20B tumor vessels. TNF-induced vascular thrombosis and subsequent
tumor necrosis are reportedly linked to a T-cell response, which is absent in the athymic
nude mice that were used in both their and our studies. They proposed that the enhanced
thrombotic effects observed in the tumor vasculature may be due to a greater proliferative
rate of tumor endothelium when compared with normal vessels or that the intrinsic
biological properties of tumor vessel may confer sensitivity to the combination of TNF
and irradiation. Holash et al. (1999) recently reported that in the development of C6
glioma, there is the presence of co-opting existing host vessels. However, the host
vasculature did not immediately undergo angiogenesis with the tumor progression.
Instead, host blood vessel regression occurred that was later followed by robust
angiogenesis. Based on all of this information, the possibility emerges that in different
stages of tumor development, the vasculature of tumor shifts from the stable host vessels
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to newly developed tumor vessels with greater abundance. Also the composition of the
expressed surface molecules on the new endothelial cells of tumor microvessels are
known to be different from those of molecules on endothelial cells on normal tissues
(Landis et ah, 1999). This hypothesis in this case still needs to be proved and future
studies in exploring the mechanism of TNF function would focus on this aspect.
Also demonstrated in this study, there also was a difference in tumor volume
between 60Co irradiated and proton irradiated tumors, as well as between the groups
receiving either 60Co or proton radiation combined with the pGLl-TNF-a plasmid.
Although there was no significant difference in parallel comparisons, average tumor
volumes of the two groups that involved proton treatment were 10%-20% smaller than
their counterparts. It was stated above that proton radiation generally has a RBE value of
1.1 compared to 60Co radiation that has a RBE value of 1.0 which reflected that proton
radiation had a stronger impact on biological tissue or organs compared to 60Co radiation.
This may very well explained the observed tumor volume differences between the two
radiation alone treated groups.
The greater biological effect of protons, as compared to gamma rays, is thought to
be due to differences in the intrinsic properties of these two forms of radiation (Eric Hall,
1998). Gamma rays, comprised of chargeless, massless photons, have few interactions
with electrons. In contrast, protons have mass and a positive charge, since they are
hydrogen nuclei. They have straight tracks because they are not deflected by the less
massive electrons with which they interact. Their direction may be altered dramatically,
however, upon occasional interaction with atomic nuclei. Thus, the amount of linear
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energy transfer (LET in KeV/|am) to proton-irradiated tissue is greater than that of
gamma radiation. The apparently greater biological effect of protons compared to
conventional gamma radiation may be advantageous in cancer therapy, especially when
coupled to superior dose versus depth properties. However, the potential for increased
effects on normal tissues also needs to be considered, since the clinical significance (if
any) of these findings is not yet known.
K. Effect of treatments on lymphocyte populations and WBC activity of C6 tumor
bearing mice
Among the 5 lymphocyte populations we analyzed with flow cytometer in the
Phase I in vivo study, there were no significant changes in the T cells or their Th and Tc
subpopulations of while TNF-oc expression was at high level 18 hr after plasmid
injection. It has been known for quite some time that the athymic mouse is not entirely
devoid of the T lineage cells (Holub, 1989 a). Report indicated that postthymic T cells
can express a thymus-independent state and can exhibit extensive self-renewal,
expansion, and functional activity in the absence of the thymus (Stutman et al. 1986).
Raff s studies have revealed small but significant numbers of Thy-1-positive cells in nude
mouse spleens and lymph nodes (Raff, et al., 1970; Raff, 1973). However, immune
competency of athymic mice was severely compromised due to the absence of normal
numbers of functional T cells. Our results here and in the other in vivo phases,
demonstrated a low level of CD3+ T cells as well as the CD3+CD4+ and CD3+CD8+
subpopulations in the blood. However, the low percentages and counts of T cells and the
lack of significant changes upon tumor and TNF-cc presence led us to the conclusion that
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the T cell mediated branch of immunity did not play a major role in our athymic mice
model against the C6 tumor. Failure of C6 tumor implantation into other strains of mice
with a competent immune system has been experienced in our laboratory before. This
would provide evidence supporting the importance of the T cell in defense against tumor.
In lymphatic tissues and in circulation, the nude mouse B cells seem to be
numerically about equal to those in euthymic mice, just stripped of the bulk of the T-cell
population (Holub 1989 b). However, optimal B cell activity is largely dependent upon T
cell help. NK cells have been rated by Kindred as the “not depressed immune
mechanisms” of nude mice (Kindred 1981). NK cells are present at high frequency in
nude mice, perhaps to compensate for the decrease in the T cell population. In our phase I
study, despite the lack of changes in the T cell population, there was a significant
decrease of B cells and a significant increase of NK cells at 18 hr after plasmid DNA
injection. The fact that the percentages and counts of both cell populations returned to
normal in the following measurements along with the decrease in TNF-a expression, led
us to believe that the changes of these two populations were caused by the expressed
TNF-a protein. In accordance with our observation, it has been reported previously that
the addition of TNF-a facilitates IL-2- dependent NK cell generation from bone marrow
progenitors (Lotzova et al., 1993). It seems that although expressed locally (no
detectable level of TNF-a was found in plasma at times of all measurements), TNF was
able to systemically affect the animals’ B and NK cell populations. The mechanism
involved in this phenomenon is not clear. In all of the flow cytometry data we obtained
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from the rest of animal studies, none of the T cells and their subsets we analyzed showed
significant difference among all tested groups, both in percentage and absolute counts.
In spleen samples that were analyzed at 1 -3 days after the last treatment in phase
II-V in vivo studies, there was a significant increase in B cell percentages while the
percentages of NK cells were significantly decreased in animals given combination
therapy. There has been no specific report to date that has outlined the movements of B
and NK cells in animals receiving treatments under the conditions of the present study.
However, it has been found that antigen stimulation can alter lymphocyte traffic patterns
by generation of host-derived factors, and extravasation of lymphocytes from blood into
non-lymphoid tissues can be induced in the skin with IFN-y and particularly TNF-a (Hay
et al., 1990). Thus the changes in B and NK cell populations that we observed in the
spleen and blood may be due to modulation of lymphocyte trafficking patterns caused by
the combination treatments.
In all phases of our in vivo studies, there were no significant changes in SI values
obtained for splenocytes upon stimulation by LPS that could be related directly to
combination treatment. This indicated that B lymphocyte’s ability to synthesize new
DNA (proliferation) in response to mitogen challenge was not significantly altered by the
combination treatment. However, spontaneous blastogenesis of blood leukocytes from
mice receiving pGLl-TNF-a injection and groups received combination treatment of
pGLl-TNF-a and radiation was increased. The values obtained were generally the
highest among all tested groups, indicating a high level of leukocyte activity was present
in the blood. This effect appeared to have been caused by an interactive effect of TNF-a
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with or without radiation. Lymphocytes are highly susceptible to very low doses of
radiation and due to rapid continuous blood circulation, and they were likely to be
exposed and impaired during tumor irradiation. Therefore, we propose that the radiationinduced depletion in lymphocytes induce hematopoietic regeneration mechanisms that
were augmented by the TNF-ct. The importance of TNF-a in this process is especially
evident in the phase I study where the highest level of spontaneous blastogenesis was
seen at 18 hr after pGLl-TNF-a injection (without radiation). As the effect on the
function of blood nucleated cells, TNF-a is a powerful neutrophil activator promoting
adherence to endothelial cells or particulate activity-stimulating phagocytosis, respiratory
burst and degranulation. TNF-a also acitivates eosinophils and is involved in the control
of B cell function particularly as a co-stimulator of B cell proliferation and
immunoglobulin (Ig) secretion (Balkwill 1989). The above stated TNF-a’s effects on the
function of WBC remained to be verified. However, it is clear from the spontaneous
blastogenesis result that the TNF-a protein produced by pGLl-TNF-a did overall
upregulate the WBC’s activity, and it seems possible that it could contribute to the
synergistic tumor inhibitiory effect of the combination treatment.
L. Tumor histopathology
There were 4 characteristics of the tumor morphology that we emphasized while
reviewing the H & E stained tumor sections: a) degrees of necrosis within the tumor, b)
nucleated cells infiltration, c) vasculature changes within the tumor and d) presence of
apoptosis. These are possible aspects by which TNF-a augmented the antitumor effect of
radiation. Although the size of tumor and necrotic region within the tumor represented
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typical tumor development, (in other words, the larger the tumor, the larger the necrotic
region within it) there were more areas that had reached late stage necrosis in tumors
receiving pGLl-TNF-a/radiation treatment. More tumor cells’ nuclei were severely
condensed even fragmented, there was more hemorrhage within necrotic region, and
there were regions present that cellular structure were absent with “nuclear dust”
scattered around the area. These observations implied that these tumors entered necrosis
earlier. During tumor progression, the center of tumor became anoxic due to poor blood
supply and therefore entered necrosis. However, the abundance of areas exhibiting late
stage necrosis in relatively small tumors that received combination treatment suggests
that the treatments also affected tumor progression. Although the exact mechanisms are
not clear, many downstream events may occur upon receiving the combination treatment.
including free radical production and nucleated cell infiltration both of which may cause
the early entry into necrosis. We did observe more PMN cells’ presence in necrotic
regions of the tumors received pGLl-TNF-cc/radiation treatments. This observation is
consistent with the proposal that combination treatment altered WBC trafficking as
discussed previously.
As stated in the result chapter, vasculature distribution and hemorrhages within
the tumor were all moderate among all tested groups and there were no obvious
differences due to the treatments. This indicates that the tumor’s vasculature was not the
major target of this combination treatment regimen. Although many groups reported that
tumor inhibitory effect of TNF-a is related to intravascular coagulation and hemorrhagic
necrosis of tumor vasculature (Balkwill 1989; Balkwill 1992; Denekamp 1993 and
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Mauceri et al, 1996), it is not seen with all tumor types and C6 glioma was not the model
used in these studies. It would be an interesting subject to explore the unresponsiveness
of C6 tumor’s vasculature to TNF.
Sporadic apoptotic bodies were found within individual tumors we examined.
However, there was no significant presence of apoptosis observed in all tested groups.
This result may well be explained by the lack of C6 cells sensitivity to TNF and the low
total dose of radiation we used. However, more precise assays for apoptosis detection are
needed before apoptosis can be entirely excluded as a possible mechanism for the
combination treatment’s tumor inhibition effect.
M. Future studies
Based on the results we have collected so far, we conclude that genetically
delivered TNF-a in combination with ionizing radiation can synergistically inhibit the
progression of the rapidly growing, radiation-resistant C6 tumor in athymic mice.
However, more studies need to be done to further improve this combination treatment
regimen and to fully understand the interactive mechanisms of the combination treatment.
The combination treatment could be tested in rats with C6 tumor implanted intracranially
to further test the feasibility of this new approach. PCR and reverse PCR design to
determine mRNA level in transfected cells would help to assess the kinetics of injected
plasmid DNA, and determine the possible factors that affect the expression level of the
TNF-a. PGL1-TNF-a could be modified, for example, to insert a radiation-inducible
promoter such as egr-1, to gain better control of TNF-a expression. Other known
antitumor agents, including cytokines, tumor suppressor and proapoptotic genes, could be
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inserted into the vector to expand the use of, as well as increase the efficacy of this gene
delivery system. Additional assays such as apoptosis detection, B and NK cell staining in
tumor sections, free radical production within the tumor, and cell surface molecule
identification on C6 vascular endothelial cells could be done to analyze the mechanisms
of the treatments.
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CHAPTER 5
CONCLUSIONS

Brain tumors are among the most frequent and difficult to treat in the human
population. Traditional therapeutic approaches against this specific type of tumor
include: surgery, chemotherapy and radiotherapy. However, there is no complete cure to
date, and the fatality rates remains high. Radiation, if given at high enough dose, can kill
any cell, but applying high dose radiation to the brain will lead to many adverse side
effects, like edema, headache and nausea. Some are more severe, like seizure and
neurological deterioration. To children, they can lead to intellectual impairment. All of
this significantly limits the use of radiation as a sole therapeutic regimen against brain
tumors. Many investigators have turned to combining radiation-sensitizing agents with
external beam radiation in an effort to enhance the overall therapeutic effects.
In an effort to establish a successful model of combination treatment against brain
tumor, we initiated the study discussed in this article. Based upon results we obtained
previously, we proposed that plasmid DNA delivered TNF-a, in combination with
ionizing irradiation, will significantly inhibit the progression of a highly aggressive,
radiation resistant C6 glioma model in athymic mice under certain conditions.
We initiated the study by synthesizing the plasmid vector for expressing TNF-a.
A universal eukaryotic expression vector pWS4 was used, based on its proven high
expression efficiency. TNF-a coding sequence was successfully inserted into the vector,
under the control of a CMV promoter, with the orientation of insertion tested. Plasmid
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DNA was successfully transfected into C6 cells in vitro by using a polyamine-facilitated
method. Expression from transfected cells was detected up to 7 days and averaged 0.4 ng
TNF-a protein in the conditioned medium (CM) from 1 x 105 cells. The expressed TNFa alone did not inhibit growth of the transfected C6 cells; neither did it modulate
radiation-induced inhibition of C6 cell proliferation in vitro. The proliferation of L929
cells (known to be TNF-a-sensitive), however, was significantly depressed by TNF-a in
supernatant from transfected C6 cells. This later observation indicated that the expressed
protein was functional. Using fluorescence-labelled monoclonal antibodies and laser
scanning cytometry (ESC), it was confirmed that both P55 and P75 receptors for TNF-a
were present on the C6 cell membrane. However, the receptors on C6 cells were
expressed at low density and with the P55 receptor being present at a significantly higher
level than P75, in contrast to what was observed with the TNF-a-sensitive L929 cells.
When plasmid pGLl-TNF-a was injected intratumorally into C6 glioma, growing
subcutaneously in athymic mice as xenografts, the injected tumors expressed significant
amounts of TNF-a in a dose-dependent manner. The expressed TNF-a protein was at
highest levels at 18 hours, and was measurable up to 7 days post-injection. In further in
vivo experiments, we demonstrated that C6 tumor progression was significantly inhibited
when pGLl-TNF-a was administered intratumorally 16-18 hours before tumor
irradiation with either conventional y-rays (60Co) or with protons. The antitumor effect of
combination therapy (3x each modality over a period of 9-10 days) was more than
additive, because the same time-dose regimen of radiation alone slowed tumor growth
only modestly and pGLl-TNF-a alone did not slow tumor growth at all. These
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experiments also showed that a relatively low dose (15 pg) of pGLl-TNF-ot could
achieve the same or better effect than higher doses (150 pg and 450 pg). The same (if
not greater) degree of tumor inhibition occurred when proton radiation was substituted
for y-radiation. The presence of a progressively growing C6 tumor has a measurable
effect on immunological status, and combination therapy did not result in prohibitive
toxicity to the animals.
Histopathological evaluation of tumors, performed several days after the last
combination treatment revealed that tumors treated with plasmid DNA expressing TNF-a
in combination with radiation started necrosis earlier than the nontreated tumors. Also
there were more neutrophils’ infiltration in necrotic regions of the tumor received
combination treatment. Analyses of blood and spleen cell populations in these mice did
not show a statistically significant difference in numbers of T (CD3+, CD4+ and CD8+)
cells, but percentages of B and NK cells in spleen did change significantly with the
animals received combination treatment. When the effects of varying doses of pGLlTNF-oc were evaluated at 3 time points within the first week after intratumoral injection,
several changes were noted, especially at the 18 hr post-injection time when pGLl-TNFa expression was at its peak and when tumor volumes were equivalent in all groups of
mice. The most relevant of these changes was a dramatic increase in the NK cells in the
blood, indicating that the expressed TNF-a was recruiting this lymphocyte population.
Collectively, the results show that the pGLl-TNF-a/radiation combination is
promising against C6 glioma, a tumor type that is virtually incurable. In addition, the
data indicate that the radiation sensitizing effect of TNF-a is indirect and probably occurs
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through multiple routes including nucleated cell trafficking, upregulation of effector cell
number and activity and early necrosis, rather than through any single major pathway.
Additional studies are needed to further reveal the possible interactions between radiation
and TNF-a, to explore the efficacy of combining radiation and other genetically
delivered antitumor agents against malignant tumors of the brain and other organs.
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APPENDIX 1
PHASE III in vivo STUDY LYMPHOCYTE INFORMATION

Phase III in vivo study Percentages of T cells and their subsets in the blood lymphocyte
population

Group
No tumor

T cells
(CD3+)
0.64 +/- 0.16b

Percentages3
Th cells
(CD4+)
0.18+/- 0.07

Tc cells
(CD8+)
0.17+/- 0.09

Nontreated tumor

0.73 +/- 0.12

0.22+/- 0.12

0.24 +/- 0.07

pGLl-TNF (150pg)

1.81 +/- 0.58

0.84 +/- 0.56

0.32 +/- 0.09

60Co

1.90+/- 0.81

0.90 +/- 0.57

0.37+/- 0.12

pWS4 (150pg)/60Co 2.43 +/- 0.73

1.20+/- 0.51

0.62 +/- 0.32

pGLl-TNF
1.28 +/- 0.38
0.50 +/- 0.34
0.17+/- 0.01
(15pg)/60Co
pGLl-TNF
1.58+/- 0.44
0.71 +/- 0.33
0.41 +/- 0.12
(150pg)/60Co
pGLl-TNF
1.53+/- 0.32
0.85 +/- 0.31
0.21 +/- 0.02
(450pg)/60Co
a
Percentages were obtained by flow cytometry analysis using fluorescence-labelled
monoclonal antibodies.
b
Mean +/- SEM; n = 5-6 mice/group.
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Phase III in vivo study counts of T cell and their subsets in blood

Group
No tumor

T cells
(CD3+)
0.035 +/- 0.009:

Nontreated tumor

Number of cells (x 10b/ml)
Th cells
Tc cells
(CD4+)
(CD8+)
0.008 +/- 0.004

0.008 +/- 0.004

0.030 +/- 0.006

0.006 +/- 0.004

0.012+/- 0.003

pGLl-TNF (150pg)

0.086 +/- 0.023

0.028+/- 0.011

0.020 +/- 0.005

60Co

0.058 +/- 0.026

0.028 +/- 0.019

0.012 +/- 0.002

pWS4 (150pg)/60Co 0.070 +/- 0.021

0.034 +/- 0.017

0.018+/- 0.008

pGLl-TNF
(15pg)/60Co
pGLl-TNF
(150pg)/60Co
pGLl-TNF
(450pg)/60Co
a
Mean +/- SEM; n =

0.033 +/- 0.009

0.013+/- 0.009

0.012+/- 0.004

0.048 +/- 0.012

0.020 +/- 0.011

0.012+/- 0.004

0.044+/- 0.011

0.024 +/- 0.011

0.006 +/- 0.002

5-6 mice/group.
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Phase III in vivo study Percentages of T cells and their subsets in spleen

Tc cells
(CD8+)

2.00 +/- 0.28b

Percentages3
Th cells
(CD4+)
0.62 +/- 0.20

Nontreated tumor

1.56+/- 0.17

0.43 +/- 0.14

0.17+/- 0.04

pGLl-TNF (150pg)

2.00 +/- 0.64

0.96 +/- 0.68

0.15+/- 0.05

60Co

1.86 +/- 0.29

0.56+/- 0.21

0.15+/- 0.04

pWS4 (15Opg)/60Co 2.52+/-0.41

1.07 +/- 0.23

0.35+/- 0.15

Group
No tumor

T cells
(CD3+)

0.22 +/- 0.07

pGLl-TNF
2.77 +/- 0.74
0.87 +/- 0.58
0.29 +/- 0.05
(15pg)/60Co
pGLl-TNF
1.97 +/- 0.28
0.59 +/- 0.21
0.21 +/- 0.03
(150pg)/60Co
pGLl-TNF
2.61 +/- 0.25
0.62+/- 0.12
0.30 +/- 0.03
(450pg)/60Co
Percentages were obtained by flow cytometry analysis using fluorescence-labelled
monoclonal antibodies.
bMean +/- SEM; n = 5-6 mice/group.
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Phase III in vivo study Counts of T cell and subsets in spleen

T cells

Number of cells (x 10(7ml)
Th cells
Tc cells
(CD4+)
(CD8+)

Group
No tumor

0.300 +/- 0.083

0.108 +/- 0.054

0.035 +/- 0.012

Nontreated tumor

0.324+/- 0.061

0.072+/- 0.016

0.038 +/- 0.009

pGLl-TNF (150pg)

0.572 +/- 0.226

0.294 +/- 0.206

0.048 +/- 0.023

60Co

0.334 +/- 0.044

0.098 +/- 0.041

0.026 +/- 0.008

pWS4 (150pg)/60Co 0.658 +/- 0.139

0.258 +/- 0.051

0.094 +/- 0.044

pGLl-TNF

0.592 +/- 0.289

0.248 +/- 0.205

0.065 +/- 0.023

0.510+/- 0.063

0.150+/- 0.047

0.054 +/- 0.07

0.786 +/- 0.105

0.194 +/- 0.039

0.088 +/- 0.008

(CD3+)

(15pg)/60Co

pGLl-TNF
(150iug)/60Co

pGLl-TNF
(450pg)/60Co

aMean +/- SEM; n = 5-6 mice/group.
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Phase III in vivo study percentages of B and NK cells in the blood lymphocyte
population
percentages3
NK cells
(NK1.1+)
14.9+/-3.3

Group
No tumor

B cells
(B220+)
84.4 +/- 3.4b

Nontreated tumor

81.2 +/- 1.5

18.1 +/- 1.6

pGLl-TNF (150pg)

77.0 +/- 4.6

21.2 +/- 4.1

60

69.8 +/- 5.6

28.3 +/- 5.7

pWS4 (150pg)/60Co

71.6+/-3.0

25.9 +/- 2.4

pGLl-TNF (15pg)/60Co

69.4 +/- 3.6

29.3 +/- 3.3

pGLl-TNF (150pg)/60Co

72.9 +/- 4.8

25.4+/- 4.6

pGLl-TNF (450pg)/60Co

70.8 +/- 3.6

27.6 +/- 3.3

Co

Percentages were obtained by flow cytometry analysis using fluorescence-labelled
monoclonal antibodies.
bMean +/- SEM; n = 5-6 mice/group.
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Phase III in vivo study B and NK counts in blood

Group
No tumor

4.28 +/- 0.75

Number of cells (x 10 /ml)
NK cells
(NK1.1+)
0.76 +/- 0.20

Nontreated tumor

3.46 +/- 0.48

0.80+/- 0.17

pGLl-TNF (150pg)

4.42 +/- 0.87

1.10+/- 0.21

60Co

2.25 +/- 0.35

0.84 +/- 0.09

pWS4 (150|ug)/60Co

2.06 +/- 0.17

0.74 +/- 0.08

pGLl-TNF (15iiig)/60Co

1.79+/- 0.18

0.77 +/- 0.11

pGLl-TNF (150pg)/60Co

2.36 +/- 0.33

0.76 +/- 0.08

pGLl-TNF (450pg)/60Co

1.97 +/- 0.21

0.78+/- 0.14

B cells
(B220+)

aMean +/- SEM; n = 5-6 mice/group.
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Phase III in vivo study B and NK cell percentages in spleen

percentages3
NK cells
(NK1.1+)
7.18+/- 0.62

No tumor

B cells
(B220+)
90.81 +/- 0.66b

Nontreated tumor

93.40 +/- 0.21

5.02 +/- 0.29

pGLl-TNF (150pg)

93.58 +/- 0.92

4.40 +/- 0.47d

60Co

93.04 +/- 0.68

5.09 +/- 0.47d

pWS4 (150pg)/60Co

93.24 +/- 0.66

4.26 +/- 0.30d

pGLl-TNF (15pg)/60Co

93.10+/- 0.53c

4.43 +/- 0.68d

pGLl-TNF (150pg)/60Co

94.08 +/- 0.66

3.96 +/- 0.54d

pGLl-TNF (450pg)/60Co

93.02 +/- 0.70

4.38 +/- 0.50d

Group

aPercentages were obtained by flow cytometry analysis using fluorescence-labelled
monoclonal
antibodies.
|_
Mean +/- SEM; n = 5-6 mice/group.
cp<0.05 vs pGLl-TNF/60Co (15pg).
dp<0.05 vs no tumor.
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Phase III in vivo study B and NK cell counts in spleen

Group
No tumor

Number of cells (x 10b/ml)
B cells
NK cells
(B220+)
(NK1.1+)
12.69 +/- 2.36a
0.788 +/- 0.174

Nontreated tumor

19.68 +/- 3.44

1.080 +/- 0.235

pGLl-TNF (150pg)

24.28 +/- 4.77

1.072+/- 0.164

60Co

17.50+/- 1.61

0.926 +/- 0.022

pWS4(150pg)/60Co

23.76 +/- 2.35

1.100 +/- 0.151

pGLl-TNF (15pg)/60Co

18.63 +/- 4.41

0.825 +/- 0.132

pGLl-TNF (150pg)/60Co

25.16+/-3.21

1.014+/- 0.104

pGLl-TNF (450pg)/60Co

28.74 +/- 3.83b

1.324 +/- 0.167

aMean +/- SEM; n = 5-6 mice/group.
bp<0.05 vs no tumor
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APPENDIX 2
PHASE V in vivo STUDY LYMPHOCYTE INFORMATION

Phase V in vivo study Percentages of T cells and their subsets in the blood lymphocyte
population

Group
No tumor

T cells
(CD3+)
0.782 +/- 0.171b

Percentages3
Th cells
(CD4+)
0.240 +/- 0.060

Tc cells
(CD8+)
0.303 +/- 0.093

Nontreated tumor

0.592 +/- 0.168

0.228 +/- 0.110

0.148 +/- 0.059

60Co

0.588 +/- 0.179

0.133 +/- 0.084

0.243 +/- 0.029

Proton

0.724 +/- 0.233

0.368+/- 0.196

0.128+/- 0.025

pGLl-TNF (150pg)

0.568 +/- 0.131

0.223 +/- 0.074

0.113 +/- 0.036

0.461 +/- 0.283
pGLl-TNF (150ug)/ 1.051 +/- 0.450
0.261 +/- 0.056
60Co
pGLl-TNF
0.828 +/- 0.092
0.322 +/- 0.084
0.262 +/- 0.054
(150pg)/proton
Percentages were obtained by flow cytometry analysis using fluorescence-labelled
monoclonal antibodies.
bMean +/- SEM; n = 5-7 mice/group.
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Phase V in vivo study counts of T cell and their subsets in blood
Number of cells (x 10°/ml)
Th cells
Tc cells
(CD4+)
(CD8+)
0.005 +/- 0.002
0.005 +/- 0.002

Group
No tumor

T cells
(CD3+)
0.017+/- 0.005

Nontreated tumor

0.018+/- 0.005

0.006 +/- 0.004

0.002 +/- 0.002

60Co

0.013+/- 0.003

0.003 +/- 0.002

0.005 +/- 0.003

Proton

0.018+/- 0.009

0.010+/- 0.008

0.004 +/- 0.002

pGLl-TNF (150pg)

0.025 +/- 0.009

0.010+/- 0.004

0.005 +/- 0.003

pGLl-TNF (150ug)/ 0.020+/-0.007
60Co
pGLl-TNF
0.022 +/- 0.004
(150pg)/proton
aMean +/- SEM; n = 5-7 mice/group.

0.009 +/- 0.006

0.004 +/- 0.002

0.012+/- 0.003

0.007 +/- 0.002
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Phase V in vivo study Percentages of T cells and their subsets in spleen

Group
No tumor

T cells
(CD3+)
2.193+/-0.263b

Percentages3
Th cells
(CD4+)
0.563 +/- 0.221

Nontreated tumor

2.880+/- 0.144

0.546 +/- 0.106

0.400 +/- 0.206

60Co

3.663 +/- 0.346

0.380 +/- 0.094

0.930+/- 0.153

Proton

4.370 +/- 0.364c

1.296 +/- 0.253

0.686 +/- 0.074

pGLl-TNF (150pg)

3.085 +/- 0.600

0.485 +/- 0.155

0.358 +/- 0.098

Tc cells
(CD8+)
0.673 +/- 0.085

0.630 +/- 0.239
0.163 +/- 0.030
pGLl-TNF (150pg)/ 3.970+/-0.260c
60Co
pGLl-TNF
3.800 +/- 0.594
0.017+/- 0.303
0.238 +/- 0.056
(150pg)/proton
"a
Percentages were obtained by flow cytometry analysis using fluorescence-labelled
monoclonal antibodies.
bMean +/- SEM; n = 5-7 mice/group.
cp<0.05 vs no tumor.
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Phase V in vivo study Counts of T cell and subsets in spleen
Number of cells (x 10°/ml)
Th cells
Tc cells
(CD4+)
(CD8+)
0.237 +/- 0.085
0.302 +/- 0.050

Group
No tumor

T cells
(CD3+)
0.970 +/- 0.141a

Nontreated tumor

0.720 +/- 0.326

0.092 +/- 0.017

0.078 +/- 0.049

60Co

0.965 +/- 0.310

0.100 +/- 0.046

0.255 +/- 0.094

Proton

1.886 +/- 0.449

0.566 +/- 0.189

0.284 +/- 0.052

pGLl-TNF (150|ug)

1.883 +/- 0.350

0.268 +/- 0.079

0.220 +/- 0.070

0.266 +/- 0.098

0.071 +/- 0.016c

0.580 +/- 0.172

0.168 +/- 0.054

pGLl-TNF (150pg)/ 1.699+/-0.267
60Co
pGLl-TNF
2.403 +/- 0.490b
(150pg)/proton
aMean +/- SEM; n = 5-7 mice/group.
bp<0.05 vs nontreated tumor.
cp<0.05 vs no tumor.
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Phase V in vivo study percentages of B and NK cells in the blood lymphocyte
population
percentages3
NK cells
(NK1.1+)

Group
No tumor

B cells
(B220+)
80.79 +/- 1.82bc

Nontreated tumor

77.38 +/- 1.51

22.02 +/- 1.49

60Co

75.06 +/- 3.44c

24.35 +/- 3.38

Proton

77.62 +/- 1.95c

21.65 +/-2.02

pGLl-TNF (150pg)

83.75 +/- 1.57

15.69 +/- 1.69

pGLl-TNF (150pg)/60Co

71.49 +/- 3.58c

27.46 +7- 3.24

pGLl-TNF (150pg)/proton

78.17 +/- 3.50

21.01 +7-3.47

18.43 +/- 1.89

aPercentages were obtained by flow cytometry analysis using fluorescence-labelled
monoclonal antibodies.
bMean +7- SEM; n = 5-7 mice/group.
cp<0.05 vs pGLl-TNF (150pg).
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Phase V in vivo study B and NK counts in blood

Group
No tumor

Number of cells (x 10(7ml)
B cells
NK cells
(B220+)
(NK1.1+)
1.872+/-0.157ab
0.430 +/- 0.060

Nontreated tumor

2.410+/- 0.186

0.680 +/- 0.058

60Co

1.610+/-0.559b

0.460+/-0.121

Proton

1.746+/-0.364b

0.456 +/- 0.065

pGLl-TNF (150jug)

3.788 +/- 0.642

0.700 +/- 0.141

pGLl-TNF (150pg)/60Co

1.650+/- 0.261b

0.580 +/- 0.055

pGLl-TNF (150pg)/proton

2.178 +/- 0.405

0.525 +/- 0.080

aMean +/- SEM; n = 5-7 mice/group.
bp<0.05 vs pGLl-TNF (150pg).
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Phase V in vivo study B and NK cell percentages in spleen
percentagesa
NK cells
(NK1.1+)
11.26 +/- 1.31°

Group
No tumor

B cells
(B220+)
86.55 +/- 1.38bc

Nontreated tumor

91.79 +/- 0.94

5.32 +/- 0.91

60Co

89.54 +/- 0.64c

6.79 +/- 0.41

Proton

90.27 +/- 0.86c

5.35 +/- 0.66

pGLl-TNF (150pg)

94.87 +/- 0.72

2.05 +/- 0.18f

pGLl-TNF (150pg)/60Co

92.23 +/- 0.36d

3.79 +/- 0.38

pGLl-TNF (150pg)/proton

93.77 +/- 1.00d

2.43 +/- 0.49 r

Percentages were obtained by flow cytometry analysis using fluorescence-labelled
monoclonal antibodies.
bMean +/- SEM; n = 5-7 mice/group.
cp<0.05 vs pGLl-TNF (150pg).
dp<0.05 vs no tumor.
ep<0.05 vs all tumor bearing group.
fp<0.05 vs 60Co.
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Phase V in vivo study B and NK cell counts in spleen
Number of cells (x l Ovml)
NK cells
(NK1.1+)
5.13 +/- 1.13°

Group
No tumor

B cells
(B220+)
37.81 +/-3.01a

Nontreated tumor

22.48 +/- 9.39c

1.19+/- 0.44

60Co

21.74 +/- 6.35c

1.69 +/- 0.53

Proton

37.99 +/- 6.60

2.21 +/- 0.41

pGLl-TNF (150pg)

59.17+/- 9.41

1.27 +/- 0.20

pGLl-TNF (150pg)/60Co

38.61 +/- 5.14

1.57+/- 0.26

pGLl-TNF (150pg)/proton

59.95 +/- 8.52

1.44 +/- 0.21

aMean +/- SEM; n = 5-7 mice/group.
bp<0.05 vs all tumor bearing groups.
cp<0.05 vs pGLl-TNF (150pg)/proton.
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